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Irish Cardiac Society Scientific Sessions
Thursday 6th October
Session 1 Electrophysiology
Chairs: Dr David Keane
18.30–21.00 Case Presentations
Session 2 Interventional Cardiology
Chairs: Dr Colm Hanratty, Prof David Foley
18.30–21.00 Case Presentations
Session 3 Peripheral Intervention
Chair: Prof Declan Sugrue
18.30–18.35 Opening Remarks
18.34–18.50 Vascular Access Complications: Endovascular Solution
Dr. Brendan Doyle
Mater Private Hospital, Dublin
18.55–19.10 Subclavian/Brachiocephalic Intervention
Dr. Tom Kiernan
Cork University Hospital, Cork










08.45–09.00 Welcome from Dr Carol Wilson, President
Session 4 Hot Topics
Chair: Dr Carol Wilson






1. Our Experience with Subcutaneous Implantable Defibrillators
Buckley U, Joyce E, Mustafa G, Keaney J, Galvin J, Keelan T, Chuktai Z, Walsh K
Miseraecordiae Hospital, Eccles Street, Dublin and the Mater Private Hospital, Eccles Street, Dublin
2. Characteristics and Outcomes of Patients Undergoing Catheter Ablation of Atrial Fibrillation at a Single Centre
Buckley U, Anwar A, Keaney J, Mustafa G, Joyce E, McCann C, Keelan T, Galvin J
The Mater Private Hospital, Eccles Street, Dublin
3. Renal Denervation for Resistant Hypertension
Mylotte D, Garot P, Unterseeh T, Louvard Y, Benamer H, Morice MC
Institut Cardiovasculaire Paris Sud, Paris, France
4. Outcome of Cardiac Surgery in Patients Initially Refused Surgery
Soo A, Nzewi O, Graham A
Department of Cardiac Surgery, Royal Victoria Hospital, Grosvenor Rd, Belfast
5. A Case Series Documenting the First Irish Experience Utilising Optical Coherence Tomography in Coronary Intervention
Phelan D, O’Sullivan B, Canniffe C, Matiullah S, Nash P, McNeill B, Crowley J, Daly K, Sharif F
Galway University Hospital, Galway
6. The Role of Cardiac MRI Perfusion in the investigation of coronary Ischaemia
Morgan RB, Waterhouse DF, Molloy E, Sheahan R, McAdam B, Gumbrielle T, Foley D, O’Hanlon R
Dept of Cardiology, Beaumont Hospital Dublin,
Cardiac MRI Unit Blackrock Clinic, Blackrock, Dublin
10.30–11.00 Poster Presentation
Coffee/Exhibition
7. Systemic Embolic Events Other than Stroke or TIA from Paradoxical Embolization via Patent Foramen Ovale
Margey R, Arzamendi D, Hynes B, Elmariah S, Renfigo-Moreno P, Schainfeld R, Jaff MR, Inglessis I, Palacios IP
Interventional Cardiology and Vascular Medicine, Division of Cardiology, Massachusetts General Hospital and Harvard
Medical School, Boston, MA
8. Contemporary Outcomes of Aortic Valve Replacement in Octogenarians
Mustafa G, Anwer A, Buckley U, Bajrangee A, Galvin J, Keelan E, Wood AE, McCarthy J, Redmond M, Hurley J, Noelke L,
O O’Neill J
Mater Misericordiae University Hospital, Dublin
9. Initial Results of Concomitant LA MAZE with Open Heart Surgery
Booth K, Dickson E, Jeganathan R, Jones M, Graham A
Royal Victoria Hospital, Belfast
10. What Does Brain Natriuretic Peptide Tell us About Progressive Left Ventricular Diastolic Dysfunction?
Collier P, Waterhouse DF, Dawkins IR, Patle AK, Watson CJ, Horgan S, Baugh JA, O’Hanlon R, Ledwidge MT,
McDonald KM
St. Vincent’s University Hospital, Elm Park, Dublin
11. Transcatheter Aortic Valve Implantation (TAVI) in the Real World
Ni Dhonnchu T, Anwar A, Keenan N, Sugrue D, Hurley J
Mater Misericordiae University Hospital, Dublin
12. A Novel Endovenous Approach for Treatment of Massive Central Venous or Pulmonary Arterial Thrombus, Mass, or
Vegetation: The AngioVac Suction Cannula and Circuit
Margey RJP, Sakhuja R, Gandhi S, R. Rogers K, Weinberg I, Jaff MR, Schainfeld R, Rosenfield K,
Section of Vascular Medicine and Peripheral Intervention, Division of Cardiology, Massachusetts General Hospital and Harvard
Medical School, Boston, USA
13. A 2-year audit of organisms and sensitivities in patients with Infective Endocarditis in a Quaternary Referral Hospital
Graham C, O’Hare K, O’Connell B, Moloney G, Young V, Tolan M, Daly C, Murphy R
St James’s Hospital, James’s Street, Dublin
S374
123
14. Initial Experience of Primary PCI for ST Elevation MI from the perspective of a non-PCI
Pal N, Byrne J, Charlton L, McClements B
Mater Hospital, Belfast Health and Social Care Trust, Belfast
15. A 24/7 Primary Percutaneous Coronary Intervention Service
Dooley M, Belfast Trust pPCI Service Group
Belfast Trust
16. Impact of Renal Insufficiency on Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention
#Margey R, *Maree AO, Selzer F, *Adams B, *Patel N, Jneid H, Marroquin OC, Mulukutla SR, §Laskey WK, *Jacobs AK
#Massachusetts General Hospital and Harvard Medical School, Boston, MA, *Boston University School of Medicine, Boston
Medical Center, Boston, MA; Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, Michael E.
DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, §University of New Mexico School of Medicine,
Albuquerque, NM
17. On-site Percutaneous Coronary Intervention (PCI) at Altnagelvin Area Hospital has led to a Significant Reduction in Time to
PCI in Patients Presenting with NSTEMI and Meets the ESC
Monaghan M, Small C, Hutchinson C, Armstrong E, Smart P, Hughes S, Purvis J, McNeill A, McGlinchey P, Moore M
Altnagelvin Area Hospital, Londonderry
18. Croi MyAction: First Results from an Innovative Community-Based Vascular Prevention Programme in Galway
1,2Flaherty G, 1Gibson I, 1Walsh AM, 1Kerins C, 4Connolly S, 1,3Crowley J
1Croi, West of Ireland Cardiac Foundation, 2National University of Galway, Ireland, 3University Hospital Galway
4Imperial College Healthcare NHS Trust, London
19. Associations Between Findings on a Cardiac Risk Assessment Questionnaire and Group 2 ECG Abnormalities: Results from the
West of Ireland Screening for Sudden Cardiac Death in Young People Study
Joyce E, Devenney D, Gargoum F, Nolan P, McGorrigan C, Crowley J, Nash P, Daly K
Galway University Hospital, Galway
20. Non-Compliant Balloons for Final Kissing Inflation in Coronary Bifurcation Lesions Treated with Provisional T-Stenting: a
Pilot Study
Mylotte D, Hovasse T, Ziani A, Lefevre T, Dumonteil N, Louvard Y, Carrie D
Institut Cardiovasculaire Paris Sud, France
Session 5 Structural Heart Disease
Chair: Dr. Kevin Walsh
11.00–11.30 ‘‘Device Regulation–the industry perspective’’
Dr. David Dunham
Regulatory Affairs Manager - UK & Ireland Medtronic Ltd.
11.30–12.30 Oral Presentations
21. Efficacy and Safety of Transcatheter Aortic Valve Implantation: Northern Ireland Experience
Manoharan G, Spence MS, Kodoth V, Maguire C, Anderson L, Doherty R, Smith B, Glover P, Manoharan GB, Tomlin A,
McKenna-Maynard M, McAllister P, Gracey H, Dixon L, Johnston N,
Royal Victoria Hospital, Grosvenor Road, Belfast
22. Initial Experience of a Mini Sternotomy Incision in Aortic Valve Replacement
Beattie GW, Nzewi OC,
Department of Cardiothoracic Surgery, Royal Victoria Hospital, Belfast
23. Atrial Septostomy for Severe Pulmonary Arterial Hypertension: Evolving Percutaneous Approaches
Roy AK, McCullagh B, Gulam M, Nashat H, Adamali H, Gaine SP, Walsh KP
Mater Misericordiae University Hospital, Dublin
24. Early Experience with the Watchman Left Atrial Appendage Occluder Device
Neylon MA, Alqaseer M, Asgedom S, Morgan R, McAdam B, Sheahan R, Foley D
Beaumont Hospital, Beaumont, Dublin
25. 25 years of Adult ECMO in Ireland: The history, development and results of the service from 1985 to 2010
Regan R




26. Actual Versus Predicted Post Ventricular Assist Device Outcomes in A Mixed Device Group: a Retrospective Study From The
National Cardiac Transplant Centre
Joyce E, Doherty M, Buckley U, Anwar A, Ni Dhonnchu T, Kinsella A, Healy D, Wood AE, Nolke L, McCarthy J, Mahon N
Mater MIsericordiae University Hospital, Eccles Street, Dublin
12.30–14.00 Lunch/Exhibition
Session 6 Imaging/Heart Failure
Chair: Dr. Angie Brown
14.00–14.30 ‘‘Can VADs replace heart transplantation? Contemporary surgical treatment for end-stage heart failure’’
Dr. Guy MacGowan
Freeman Hospital, Newcastle upon Tyne, UK
14.30–15.30 Oral Presentations
27. The Early Role of CMR in the Assessment of Cardiomyopathy
Barrett M, Waterhouse DF, Morgan RB, Molloy E, Sheahan R, McAdam B, Gumbrielle T, Foley D, O’Hanlon R
Cardiac MRI Unit, Blackrock Clinic, Blackrock, Co. Dublin
28. Cardiac MRI Findings in Hypertrophic Cardiomyopathy: a Northern Ireland Population
1Lyons K, 2Dixon L, 2Johnston N, 3Horan P
1Belfast City Hospital, 2Royal Victoria Hospital, 3Antrim Area Hospital
29. Atrial and Ventricular Functional Changes on Echocardiography in Newly Diagnosed Untreated Hereditary Haemochromatosis
Almuntaser I, King G, Norris S, Daly C, Ellis E, Murphy R
Departments of Cardiology and Hepatology, St James’s Hospital, Dublin
30. Is There a Mortality Risk Associated with Aspirin use in Heart Failure? Results from a Large Community Based Cohort
1,2Bermingham M, 1Shanahan MK, 1Miwa S, 1Dawkins I, 1O’Hanlon R, 1,2McDonald K, 1,2Ledwidge M
1Heart Failure Unit, St Vincent’s University Hospital
2School of Medicine and Medical Science, University College Dublin
31. Detection of High Sensitivity TNT Using Fourth Generation Immunoassay in Pulmonary Hypertension Patients Identifies a
Subgroup with More Advanced Disease
Roy AK, McCullagh B, McGorrian C, Russell C, Fitzgibbon M, Murray PT, Gaine SP
Mater Misericordiae Hospital, Dublin
32. Does Right Ventricular Function Alone Predict Outcomes After CRT? An Analysis of the MADIT-CRT Population
Campbell P, Takeuchi M, l Bourgoun M, Foster E,. Brown MW, Moss AJ, Pfeffer MA, Solomon SD
Brigham and Women’s Hospital, Boston, Mass. USA
15.30–16.00 Poster Presentations
Coffee/exhibition
33. Comparison of Traditional and Novel Definitions of Acute Kidney Injury for the Prediction of Outcomes in Acute
De-Compensated Heart Failure
Roy AK, McGorrian C, Nashat H, Tracey C, Kavanaugh E, Brennan A, Maksudova N, Mahon NG, Murray PT
Mater Misericordiae University Hospital, Dublin
34. Biological Variability of Bioelectrical Impedance Testing in a Cardiac Inpatient Setting
Mak G, Murtagh G, O’Connell R, Dawkins I, O’Hanlon R, Ledwidge M, McDonald K
St. Vincent’s University Hospital, Dublin
35. Screening for Asymptomatic Left Ventricular Dysfunction Using B-Type Natriuretic Peptide: Effect of Left Ventricular
Diastolic Dysfunction on Results: a Report from the STOP-HF Study
Murtagh G, Dawkins IR, Ledwidge MT, Tallon E, O’ Hanlon R, McDonald KM
St Vincent’s University Hospital, Heart Failure Unit, Dublin
36. B-Type Natriuretic Peptide Response with Peak Exercise and Symptom Reproduction in Determining Heart Failure Diagnosis
in a New Diagnostic Heart Failure Clinic: Interim Analysis
Voon KJ, Murtagh G, Badabhagni M, Patle A, Ledwidge MT, O’Hanlon R, McDonald KM
St. Vincent’s University Hospital, Dublin
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37. Undertreatment of Asymptomatic Left Ventricular Dysfunction: a Report from the STOP-HF Study
Murtagh G, Dawkins IR, Ledwidge MT, Tallon E, O’ Hanlon R, McDonald KM
St Vincent’s University Hospital, Heart Failure Unit, Dublin
38. The Benefits of the Use of Chronic Phosphodiesterase 5 Inhibitors (PDE5) in Patients with Heart Failure with Reduced Ejection
Fraction and Secondary Pulmonary Hypertension: a Single Center Study
Al Qaseer M, Raleigh C, Egan S, Brendan McAdam
Beaumont Hospital, Beaumont, Dublin
39. The Use of Ivabradine in Eligible Heart Failure Population
Khider W, Boles O
Our Lady of Lourdes Hospital, Drogheda, Co. Louth
40. Cost Effectiveness of Adding CMR to Evaluation of Suspected Coronary Ischaemia
Waterhouse DF, Barrett M, Morgan RB, Molloy E, Sheahan R, McAdam B, Gumbrielle T, Foley D, O’Hanlon R
Cardiac MRI Unit, Blackrock Clinic, Blackrock, Co. Dublin
41. B-Type Natriuretic Peptide Association with Persistent Non-Dipping Nocturnal Blood Pressure in Patients with Hypertension
and Diabetes After 1 year-Early Markers of Diabetic
Voon KJ, Phelan D, Watson CJ, Bhutta U, Elrasheed O, Murphy N, O’Hanlon R, Ledwidge MT, Ledwidge MT, O’Shea D,
McDonald KM
St Vincent’s University Hospital, Elm Park, Dublin
42. Establishing a Cardiac MRI Programme In Ireland: 1-Year Experience
Waterhouse DF, Barrett M, Morgan RB, Molloy E, Sheahan R, McAdam B, Gumbrielle T, Foley D, O’Hanlon R
MRI Department, Blackrock Clinic, Blackrock, Co. Dublin
43. Coronary Calcium is More Effective than Diamond Forrester for Cardiology Resource Utilisation at RACPC
McKavanagh P, Donnelly PM, Ball P, Harbinson M, Trinick T, Lusk L, Doyle P,
Ulster Hospital, Dundonald, Belfast
44. Increase in Isovolumic Acceleration (IVA) of the Right Ventricular (RV) Free Wall but No Difference in NT-proBNP Between
Endurance Athletes with Athlete’s Heart and Healthy Untrained Controls at Rest
McLoughlin B, Flynn I, Clarke J. King G
Eagle Lodge Cardiology. Limerick
45. Atrial Septal Pouches: Can they be Identified on Transoesophageal Echocardiogram?
O’Flynn AM, Moore DP
The Adelaide & Meath Hospital incorporating the National Children’s Hospital (AMNCH), Tallaght, Dublin
46. Cardiac CT in an Emergency Department Chest Pain Evaluation Unit in Ireland
1Kearns G, 1Erwin J, 1Keane D, 1McCreery C, 1McDonald K, 1Quigley P, 1Quinn M, 2Dodd, J
1Department of Cardiology, St. Vincent’s University Hospital, Elm Park, Dublin
2Department of Radiology, St. Vincent’s University Hospital, Elm Park, Dublin
Session 7 Young Investigator’s Award
Chair: Dr. Carol Wilson
Judges: Prof. David Wood, Dr. Peter Wilmshurst, Dr. Peter Kearney
16.00–17.0 Oral Presentations
47. Potent Long-term Cardioprotective Effects of Single Low Dose Insulin-like Growth Factor-1 (LD-IGF-1) Treatment Post
Myocardial Infarction
O’Sullivan J F, Leblond AL, Kelly G, Kumar A HS, Metharom P, Bu¨neker CK, Alizadeh-Vikali N, Hristova I, Hynes BG,
O’Connor R, Caplice NM,
Centre for Research in Vascular Biology, Biosciences Institute, UCC, Cork
48. Waveform Optimisation for Internal Cardioversion of Atrial Fibrillation
1Kodoth V, 2Castro NC, 1Glover BM, 3Anderson JM, 3Escalona OJ, 1Lau E, 1Manoharan G
1The Heart Centre, Royal Victoria Hospital, Belfast, NI
2Department of Electronics, Universidad Simon Bolivar, Caracas, Venezuela
3Northern Ireland Bio-Engineering Centre, University of Ulster, Jordonstown, NI
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49. LRG: a Novel Biomarker of Ventricular Dysfunction and Heart Failure
*Watson C J, *Ledwidge MT, *Phelan D, *Collier P, *Byrne JC, *Dunn MJ, *§McDonald KM, *§Baugh JA
*School of Medicine & Medical Science, St Vincent’s University Hospital & The Conway Institute of Biomolecular and
Biomedical Research, University College Dublin
Heart Failure Unit, St Vincent’s University Hospital Healthcare Group, Elm Park, Dublin
§ Denotes equal author contributions
50. Exercise Training Improves Activity and Psychosocial Wellbeing in Adolescents with Congenital Heart Disease (CHD)
1Morrison ML, 1Sands AJ, 1,2McCusker CG, 2McKeown PP, 1McMahon M, 1Gordon J, 1Craig BG, 1Casey FA
1Department of Paediatric Cardiology, The Royal Belfast Hospital for Sick Children, Belfast
2The Queen’s University of Belfast, Belfast
17.100–17.30 ICS AGM
17.45–18.45 Stokes Lecture
‘‘Protectig the heart and circulation’’
Prof. David Wood
Garfield Weston Professor Cardiovascular Medicine,
International Centre for Circulatory Health,




08.00–09.15 Cardiology Education and Training Update
Chairs: Dr Peter Kearney & Dr Tom Trouton
Session 8 Revascularisation
Chair: Dr. Andrew Maree
09.15–10.00 Primary PCI
The Belfast Experience Dr. Paul Johnston
The National PPCI Plan Dr. Niall Mulvihill
The UK Experience Dr. Mark de Belder
Discussion
Oral Presentations
51. Duration of Balloon Inflation for Optimal Stent Deployment: 5 Seconds is Not Enough
Mylotte D, Hovasse T, Garot P, Salvatella N; Morice MC, Chevalier B, Pichard A, Lefe`vre T
Institute Cardiovasculaire Paris Sud
52. Syntax Scoring in Multivessel Coronary Artery Disease: a Multidisciplinary Approach is Best
Hodkinson EC, Noad RL, Spence MS, Johnston PWJ
Cardiology Department, Royal Victoria Hospital, Belfast Trust, Belfast
53. Total but not Partial Discontinuation of Antiplatelet Therapy in ACS Presenters Predicts Poor Clinical Outcome
O’Connor S, Collet JP, Hattab M, Tanguy ML, Silvain J, Barthelemy O, Bellemain-Appaix A, Beygui1 F, Montalescot G
Institut de Cardiologie, INSERM CMR937, Pitie´-Salpeˆtrie`re Hospital (AP-HP) 75013 Paris, France Universite´ Pierre et Marie
Curie, Paris, France
54. Impact of Renal Insufficiency on Prescription of Discharge Medication and 1-year Outcomes After Percutaneous Coronary
Intervention
#Margey R, Selzer F, *Quiroz R, Jneid H, Marroquin OC, Mulukutla SR, §Laskey WK, *Jacobs AK,* Maree AO
#Massachusetts General Hospital, Harvard Medical School, Boston, MA; *Boston University School of Medicine, Boston
Medical Center, Boston, MA; Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Michael E.
DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX; §University of New Mexico School of Medicine,
NM
55. In Primary Percutaneous Coronary Intervention Mortality is Low and Largely Predictable




56. Single Centre Experience of Contemporary Rotablation Atherectomy
Pal N, Spence M, Manoharan G, Dalzell G, Wilson C, Hanratty C, Walsh S, Riddell J, Johnston P
Royal Victoria Hospital, Belfast
11.00–11.30 Poster Presentation
Coffee
57. Re-Fibrillating the Atrium with Low Energy, Synchronized Shocks After DFT testing
Cronin EM, Baranowski BJ, Chung R, Wazni O, Kanj M, Saliba W, Callahan T, Borek P, and Martin DO
Cleveland Clinic, Cleveland, OH, USA
58. A Comparison of Complication Rates Between Active and Passive Pacemaker Leads
Matiullah S, Canniffe C, Boyle M, Aziz W, Phelan D, O’Sullivan B, Daly K, Crowley J, Sharif F, MacNeill B, Nash P
Galway University Hospital, Galway
59. Varying Prevalences of Chronotropic Incompetence from Different Disease Definitions
J Groarke, R Y Lim, P Owens, AO Maree
Department of Cardiology, Waterford Regional Hospital, Waterford
60. Implantable Cardioverter Defibrillator Therapy in a Mixed Adult Congenital Heart Disease Population
Joyce E, O’Brien C, Buckley U, Keaney J, Doran E, Savage R, Walsh K
Mater Misericordiae Hospital, Eccles St, Dublin
61. The Degree of QRS Shortening After Resynchronization Therapy as a Predictor of LV Reverse Remodeling: a Long Term
Retrospective Observational Study in a Single Irish Center
AlQaseer M, Jamshaid M, Collis R, Collins A, Sheahan R
Beaumont Hospital, Beaumont, Dublin
62. Sprint Fidelis Lead Failure: a Report from Northern Ireland
1Kodoth V, 2Gordon B, 1Ashfield K, 1 Lau E, 1Wilson C, 2Chew EW, 1Roberts MJ
1The Heart Centre, Royal Victoria Hospital, Belfast
2Cardiology department, Belfast City Hospital, Belfast
63. An Overview of Pacemaker and Device Implantations in the West of Ireland
Canniffe C, Matiullah S, Aziz W, Boyle M, O’Sullivan C, Phelan D, Daly K, Crowley J, Nash P, Sharif F, MacNeill B
Galway University Hospital, Galway
64. Primary Percutaneous Coronary Intervention ‘‘False Positives’’
Dooley M, Belfast Trust pPCI Service Group
Belfast Trust, Belfast
65. Impact of Targeted Subspecialist Care Versus Generalist Care on Lengths of Hospital Stay and Costs across Common Diagnostic
Groups
Groarke J, Maree AO, Owens P
Department of Cardiology, Waterford Regional Hospital, Waterford
66. Constrictive Pericarditis, Still a Diagnostic Challenge in the Twenty-First Century: an Irish Single-Centre Retrospective Cohort
Study
Moran DP, Khalil A, O Donnell A, Kiernan TJ
Dept of Cardiology and Cardiothoracic Surgery, University College Cork, Cork University Hospital, Cork
67. Percutaneous Left Atrial Apendage Closure (PLAATO): 5-year Outcomes
Neylon MA, O’Connor SA, Mylotte D, McAdam B, Sheahan R, Foley D
Beaumont Hospital, Beaumont, Dublin
68. Real World Costs of Non-Cardiac Chest Pain Admissions
Groarke J, O’Brien J, Go G, Susanto M, Owens P, Maree AO
Department of Cardiology, Waterford Regional Hospital, Waterford
69. Evolving Trends of Intra-Aortic Balloon Pump Counterpulsation (IABP) Usage in a Tertiary Cardiac Transplant Centre from
2008 to 2010
Anwar AA, Roy A, Mustafa G, Joyce E, Buckley U, Nashat H, Sugrue D, McCann H, Blake G, Mahon N
Mater Misericordiae Hospital, Dublin
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70. Atrial Fibrillation in Paced Rhythm: ‘‘Under-Diagnosed and Under-Recognized’’
Alkhalil M, Quinn S, Magill P, Tauro R, Prabhavalkar S
Belfast Health & Social Care Trust, Belfast
71. Cardiac Contribution to the Workload of Medical Assessment Units (MAUs)
Groarke J, McMenamin L, McConway L
Medical Assessment Unit, Waterford Regional Hospital, Waterford
Session 9 Electrophysiology/General Cardiology
Chair: Dr. Joe Galvin








72. Cost and Resource Implications of Defibrillator Lead Fractures
1,2Groarke J, 2Buckley U, 1Collison D, 2O’Neill, 2Mahon N, 1Foley B
1St. James’s Hospital, Dublin;
2Mater Misericordiae University Hospital, Dublin
73. Riata Lead Failure: a Report from Northern Ireland (NI) Riata Lead Screening Programme
Kodoth V, Cromie N, McEneaney D, Wilson C, Lau E, Roberts MJ
Royal Victoria Hospital, Belfast
74. Atrial Fibrillation in Ireland. Highly Symptomatic and Associated with a High Incidence of Co-Morbidities: Insights from the
RealiseAF Registry
O’Neill J, Keelan T, Galvin J, Conway M, Gumbrielle T, Sheahan R, McFadden E, Murphy R, McCaffrey D
On behalf of the RealiseAF Irish Investigators
75. Long Term Outcomes in Patients Receiving Cardiac Resynchronization Therapy: a 10-year Single Center Irish Registry
AlQaseer M, Jamshaid M, Collis R, Collins R, Wotchcorn R, Sheahan RG
Beaumont Hospital, Dublin
76. Use of the Stand-Up Test for the Long QT Syndrome in a Screening Population for Inherited Cardiac Diseases
McGorrian C, Constant O, O’Donnell C, Keelan T, Galvin J, O’Neill J, Mahon N
The Heart House, Mater Misericordiae University Hospital, Dublin
77. Out of Hospital Cardiac Arrest: a Review of Ambulance Data in Dublin Mid-Leinster
1Burke J. 2Kelleher C
1UCD School of Nursing Midwifery and Health Systems, Dublin
2UCD School of Public Health, Physiotherapy and Population Science, Dublin
13.00 Close of meeting
S380
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Session 4: Hot Topics
Oral Presentations
1. Our Experience with Subcutaneous Implantable
Defibrillators
Buckley U, Joyce E, Mustafa G, Keaney J, Galvin J, Keelan T,
Chuktai Z, Walsh K
Miseraecordiae Hospital, Eccles Street, Dublin and The Mater Private
Hospital, Eccles Street, Dublin
Aim: To review the patients receiving the ‘Cameron’ subcutaneous
implantable defibrillator system (ICD). Subcutaneous ICDs may have
potential benefits over the conventional transvenous system due to
less risk of complications. The pulse generator and the electrode are
implanted subcutaneously in the thoracic region. An electrode with an
8 cm coil and two sensing electrodes are implanted adjacent to the
manubrio-sternal joint and the xiphoid process. No fluoroscopy is
required. The procedure is performed in the cardiac theatre instead of
the catheterisation laboratory.
Method: We reviewed the patients receiving the novel subcutaneous
implantable defibrillator in the Cardiology Department of the Mater
Misericordiae Hospital and the Mater Private Hospital.
Result: Five male patients received the ‘Cameron’ subcutaneous
implantable defibrillator. The average age was 38.2 (18–71). Of these
patients, three had prior transvenous systems explanted due to com-
plications; one with a lead fracture, the second patient had septic
emboli from an infected defibrillator lead, and the third with device
erosion requiring explant. The indications for implantation were as
follows: one with hypertrophic obstructive cardiomyopathy with lv
septal myomectomy (primary prevention), one hypertrophic cardio-
myopathy (secondary prevention, prior ventricular fibrillation), one
dilated cardiomyopathy (DCM) with prior atrial septal defect closure
and left ventricular function 20% (primary prevention), one DCM, one
ischaemic cardiomyopathy and one patient with complex congenital
heart disease resulting in progressive systemic right ventricular failure
secondary to transposition of the great arteries, prior ventricular septal
defect and mustard procedure (primary prevention). All five patients
underwent successful implantation of the subcutaneous device. Ven-
tricular fibrillation was successfully detected and terminated with
maximum output 65 J therapy in all patients. There were no compli-
cations during device implantation. The average duration since
implant is 3.6 months (2–6) and at subsequent device interrogations
one patient has under sensing of premature ventricular complexes.
Conclusion: As this new device sits entirely outside the thoracic
cavity it avoids complications such as pneumothorax, difficulty
accessing the venous system, cardiac perforation, lead fracture and
in the case of the need for lead explant it would not be associated
with the same risks. The clinical utility may be in patients requiring
ICD therapy but who do not require bradycardia pacing or cardiac
resynchronization therapy.
2. Characteristics and Outcomes of Patients
Undergoing Catheter Ablation of Atrial Fibrillation
at a Single Centre
Buckley U, Anwar A, Keaney J, Mustafa G, Joyce E, McCann C,
Keelan T, Galvin J
The Mater Private Hospital, Eccles Street, Dublin
Aim: We sought to assess the patient selection and outcomes in atrial
fibrillation (AF) ablations in our centre.
Methods: We reviewed all patients who continue to follow up in the
Mater Private Hospital undergoing atrial fibrillation ablations between
January 2006 and September 2010. The data were retrospectively
collected by examination of procedure reports and clinic letters stored
on patients’ electronic medical record. The techniques used were
lasso-guided circumferential focal ablation using fluoroscopy,
CARTO or NAVEX imaging systems and irrigated 4 mm tip radio-
frequency catheters, dual phased non-irrigated circular ablation
frontiers PVAC, Bard mesh array catheters or cryoballoon catheters
for lesion creation.
Results: Two hundred and forty-eight ablation procedures for AF were
performed in 131 patients (80% male) between January 2006 and
September 2010. The mean duration of follow up was 16.35 months
(range 1–57). The average age was 55 years (range 30–74) and 54%
had more than one procedure. The mean duration of arrhythmia was
5.6 years (range 1–23). Left ventricular dysfunction was present in
13.7%. On the day of the procedure the rhythm was deemed to be long
term persistent in 12.9%, persistent in 50%, and paroxysmal AF in
36%. There was a blanking period of 6 weeks post procedure. Post AF
ablation there were 56% of patients in sinus rhythm, 33% paroxysmal,
4.5% persistent and 5.3% long term persistent AF (Table 1). The
complication rate was 5.6% of total number of procedures performed,
with six pericardial effusions (5 with tamponade and one requiring
emergency cardiothoracic surgery), three venous puncture complica-
tions, one cerebrovascular accident, one phrenic nerve palsy, one
pulmonary vein stenosis, and two with pericarditis.





Paroxysmal AF 49 36 (73%)
Persistent AF 65 37 (56.9%)
Long term persistent AF 17 6 (35%)
Conclusion: Catheter ablation of AF in this cohort of patients proved
feasible with a low risk of serious complications and no long term
adverse sequelae. Recurrence of atrial fibrillation was highest in those
with long term persistent AF at baseline (65%), and lowest in those
with paroxysmal AF (27%). Most common cardiac arrhythmias and
123
Ir J Med Sci (2011) 180 (Suppl 11):S371–S409
DOI 10.1007/s11845-011-0752-y
ideally should be performed for paroxysmal fibrillation before per-
sistent or long term persistent fibrillation develop.
3. Renal Denervation for Resistant Hypertension
Mylotte D, Garot P, Unterseeh T, Louvard Y, Benamer H, Morice MC
Institut Cardiovasculaire Paris Sud, Paris, France
Introduction: Renal denervation has recently emerged as a novel
treatment strategy for resistant hypertension. However, the only data
available supporting this therapy is from a single randomized con-
trolled trial, of highly selected patients.
Objectives: The aim of this study is to assess the efficacy of renal
denervation in a large cohort of relatively unselected patients with
resistant hypertension, and to identify predictors of treatment success/
failure.
Methods: In order to meet the study objectives, we recruited con-
secutive patients with treatment-resistant hypertension into a
prospective multicentre registry, at two French centres. Hypertension
was assessed by twice-daily home BP measurements for 2 weeks, and
with ambulatory BP monitoring for 24-h prior to study enrolment.
Assessment of patient medication compliance was performed with a
standardized questionnaire. In addition, all patients underwent
screening renal artery anatomical evaluation to confirm anatomical
eligibility. Baseline laboratory analyses were performed prior to study
inclusion. Clinical follow-up with office, home and 24 h ambulatory
BP measurements are performed at 1, 6 and 12 months.
Results: Preliminary data is available on 30 patients; mean age
66 ± 9.2 years; 23.3% female; mean duration of hypertension
12.0 ± 4.1 years; mean number of antihypertensive medications
5.0 ± 1.0. Among these patients, 10.0% had significant renal dys-
function. Procedural success was achieved in all patients with a mean
5.0 ± 1.1 ablations performed for each renal artery. There were no
procedural complications. Prior to renal denervation, the average
systolic and diastolic BP on ambulatory monitoring was 158.2 ± 21.7
and 87.1 ± 7.7 mmHg, respectively. At 1-month follow-up, the
mean BP on ambulatory monitoring were 132.3 ± 22.1 mmHg
(p \ 0.0001) and 71.4 ± 7.8 mmHg (p \ 0.0001), respectively.
Conclusions: Preliminary data suggests that renal denervation results
in highly significant BP reductions in patients with resistant hyper-
tension at 1 month. Additional information will be available for
presentation in October 2011.
4. Outcome of Cardiac Surgery in Patients Initially
Refused Surgery
Soo A, Nzewi O, Graham A
Department of Cardiac Surgery, Royal Victoria Hospital, Grosvenor
Rd, Belfast
Objectives: Despite advancement in medical therapies, surgery
remains an important treatment option for cardiac diseases. As the
population ages, patients present with more complex cardiac prob-
lems and comorbidities. This contributes to increased surgical risk.
With stringent auditing and open publication of surgical results, some
surgeons may opt to turn down such high risk patients denying them a
potentially lifesaving procedure. In this study, we aim to examine the
results of patients who were operated on following an initial refusal
for surgery.
Methods: Data was collected retrospectively from the local hos-
pital database (Intellect) over a 10-year period. Patients included in
the study had previously been turned down for open heart surgery
by a consultant cardiac surgeon and subsequently underwent the
same surgery performed by a different surgeon. Data examined
included reasons for surgical refusal, estimated surgical risk, and
outcome.
Results: 64 patients were included in the study. The commonest
reason offered for surgical refusal was significant patient comorbidity
(29.7%) Other reasons included poor coronary target for revascular-
isation (20.3%), poor heart function (17.2%), advanced age (3.1%),
lack of conduit (3.1%) and obesity (3.1%). The average Euroscore for
this group of patients were 8 ± 3% (additive) and 15.9 ± 14.5%
(logistic). There were six hospital mortalities in this series (9.3%).
The observed:expected mortality rate was 0.58.
Conclusion: In this study, patients who were operated on following a
first time refusal of surgery had better than predicted outcomes, as
predicted by conventional risk assessment. Therefore, we advocate
that a second opinion should be routinely sought for patients who had
been turned down for surgery.
5. A Case Series Documenting the First Irish
Experience Utilising Optical Coherence Tomography
in Coronary Intervention
Phelan D, O’Sullivan B, Canniffe C, Matiullah S, Nash P, McNeill B,
Crowley J, Daly K, Sharif F
Galway University Hospital, Galway
Cardiovascular optical coherence tomography (OCT) is a catheter-
based invasive imaging system. Employing light rather than ultra-
sound, OCT produces high-resolution in vivo images of coronary
arteries. The image is formed by the backscattering of light from the
vessel wall. Using a wavelength of 1,300 nm the tissue penetration
is limited to 1–3 mm as compared with 4–8 mm achieved by
intravascular ultrasound (IVUS). However OCT offers significantly
improved axial resolution (12–18 vs. 150–200 lm) and lateral res-
olution (20–90 vs. 150–300 lm) when compared to IVUS. The new
frequency domain OCT systems can acquire 100 frames/s and have
pullback speeds of up to 20 mm/s with the ability to scan 4–6 cm
length epicardial coronary vessels in \5 s. These pullback speeds
permit the use of a single, high rate (4 cc/s) bolus injection of
contrast to produce a blood-free environment. Images are recorded
by a fiberoptic wire that rotates inside a fluid-filled polymer tube
which is compatible with 6-F guiding catheters. It is advanced
distally to the segment of interest over a conventional angioplasty
guidewire (0.014 in.). In our initial experience with the OCT we
noticed superior coronary imaging including minimal lumen area,
percentage lumen obstruction, percent neointimal hyperplasia, stent
apposition and stent expansion. In addition, OCT is also useful for
evaluating minimal stent cross section area, lumen gain and late
lumen loss. All these parameters are based on the evaluation of the
lumen-vessel/stent interface where OCT can be potentially useful
clinically. Plaque protrusion and stent-edge dissection are other
common intervention-related parameters readily visible on OCT
images. Given its high resolution, OCT has the potential for
improved tissue characterisation. Fibrous cap thickness may also be
measured and unlike IVUS OCT can penetrate calcium and can
identify thrombus. The main drawback of OCT is the requirement of
blood clearing for imaging which can potentially increase the con-
trast load, especially if multiple runs are required. Here we present
the first Irish experience using OCT in 20 patients and describe the




6. The Role of Cardiac MRI Perfusion
in the Investigation of Coronary Ischaemia
Morgan RB, Waterhouse DF, Molloy E, Sheahan R, McAdam B,
Gumbrielle T, Foley D, O’Hanlon R
Department of Cardiology, Beaumont Hospital Dublin, Cardiac MRI
Unit Blackrock Clinic, Blackrock, Dublin
Background: Cardiovascular magnetic resonance imaging (CMR) is
an advanced imaging modality to evaluate cardiac structure, function,
myocardial fibrosis/infarction and inducible myocardial ischaemia. A
recent large European registry highlighted the role of CMR in a wide
array of cardiovascular conditions, avoiding the need for further
imaging. A safe imaging technique, it avoids the need for ionising
radiation providing prognostic information, influencing patient man-
agement and potentially avoiding the need for other investigations.
Methods: Over a 12-month period, 178 patients were referred for
CMR. 111 underwent adenosine perfusion imaging to detect/quantify
inducible ischaemia. Patient data was collected through outpatient
and chart review. Data was analysed utilising SPSS software.
Results: Of 111 patients assessed for ischaemia 59.5% were male, mean
age 63 years (±12 years). Indications for perfusion CMR were:
equivocal stress test (11%); chest pain with normal coronary angiog-
raphy (10%); assessment of functional significance of coronary lesions
(46%); viability (17%) and other (16%). CMR established the diagnosis
accurately in 96.4% of patients. A new diagnosis was made in 42%
(including inducible ischaemia, AS, non-cardiac findings). CMR find-
ings impacted management decisions in 88% of cases—medication
changes in 27%; percutaneous intervention indicated in 33% of patients;
surgery (incl. ICD implantation) was indicated in 9%; Invasive angi-
ography +/- PCI was indicated in 27%. In 16% of cases, patients were
discharged and in 35% invasive angiography was avoided as a result of
reassuring cardiac MRI findings—of this cohort, 9 patients (8%) have
had a cardiac admission over the period of follow up-ave 7.5 months.
Further investigation with repeat CMRI was advised 11% of patients.
Conclusion: CMR is an invaluable tool in the evaluation of cardiac
patients and has an important impact on patient management with the
potential to target appropriate investigations and interventions in
specific groups.
Poster Presentation
7. Systemic Embolic Events Other than Stroke or TIA
from Paradoxical Embolization via Patent Foramen
Ovale
Margey R, Arzamendi D, Hynes B, Elmariah S, Renfigo-Moreno P,
Schainfeld R, Jaff MR, Inglessis I, Palacios IP
Interventional Cardiology and Vascular Medicine, Division of
Cardiology, Massachusetts General Hospital and Harvard Medical
School, Boston, MA
Background: Patent foramen ovale (PFO) and its association with
cryptogenic stroke in the young is well established. However, para-
doxical embolization to the extracranial arterial circulation is poorly
characterized.
Methods: From 832 patients undergoing transcatheter closure of PFO
between 2001 and 2010; we identified 29 cases in which the indica-
tion for closure was non-cerebrovascular embolic events representing
3.5% of cases. Demographic, clinical, procedural characteristics plus
immediate and long-term follow-up were described.
Results: Presentation: six Acute MI, nine retinal emboli, six renal
infarctions, three radial artery occlusions, three splenic infarcts, and
two lower extremity arterial emboli. Mean age was 46.4 years
(±14 years). M: F ratio 1:1.1. 21/29 (72%) were not on anti-throm-
botic or anticoagulant agents at presentation, 7/29 (28%) were on
aspirin alone. 11 cases (38%) had co-existent May-Thurner syndrome.
13 patients had atrial septal aneurysm or hypermobile septum. 13/29
(44.8%) had a positive hypercoagulable screen. In two cases, no PFO
could be identified at angiography. 17/27 (58%) were closed with an
Amplatzer Cribriform device, 5 Helix device, 3 Cardioseal device, 2
with an Amplatzer ASD device. Procedural successful was 100%. In-
hospital, one Helix device embolization occurred—successfully
retrieved percutaneously; an Amplatzer device was placed instead. No
other in-hospital or vascular access complications occurred. 12
patients were treated with anti-platelet monotherapy, 5 with dual anti-
platelet therapy, 3 with warfarin, and 9 with combination warfarin and
aspirin. In follow-up, no AI developed; effective defect closure was
100% with no significant residual shunting. No further arterial
embolic events or device embolization occurred. Median follow-up
was 376 days (11–2,195 days).
Conclusions: This represents the largest case series of PFO associ-
ated non-cerebrovascular paradoxical emboli. Screening for
hypercoagulable defects and co-existent May-Thurner syndrome in
these cases is warranted due to their high occurrence. These patients
can be successfully treated with transcatheter defect closure, with no
recurrent events in follow-up.
8. Contemporary Outcomes of Aortic Valve
Replacement in Octogenarians
Mustafa G, Anwer A, Buckley U, Bajrangee A, Galvin J, Keelan E,
Wood AE, McCarthy J, Redmond M, Hurley J, Noelke L, O O’Neill J
Mater Misericordiae University Hospital, Dublin
Introduction: The number of elderly patients requiring aortic valve
replacement (AVR) continues to increase. Transcutaneous aortic
valve intervention is gaining acceptance as an alternative to open
heart surgery for people with symptomatic aortic stenosis and sig-
nificant comorbidities, often in very elderly patients. However,
conventional AVR remains the procedure of choice for elderly
patients with aortic valve disease who are surgical candidates. We
sought to describe contemporary outcomes in elderly ([80 years old)
patients undergoing conventional AVR.
Methods: We retrospectively identified patients [80 years old who
underwent AVR alone or AVR in combination with coronary artery
bypass grafting (CABG) at the Mater Misericordiae University Hos-
pital, Dublin, Ireland between 2005 and 2010. Clinical records were
obtained and reviewed. Data are presented as mean ± SD unless
otherwise stated.
Results: Over 5 years, 68 patients (29 men and 39 women, mean
82 ± 2.2 years) underwent open heart surgical AVR. Operative
mortality was 8.8% (6/68). The median length of stay in the hospital
was 21 days. Symptoms before surgery were dyspnoea in 92.6%,
chest pain in 78%, and syncope in 25%. Before AVR, 9% patients had
renal impairment, 13% had atrial fibrillation, 47% had left ventricular
systolic dysfunction, 78% had concomitant coronary artery disease,
3% had prior CABG, 57% had hypertension and 10% had diabetes
mellitus. Post surgery, the percentage of patients who developed new
onset atrial fibrillation, renal failure, and stroke were 47, 22 and 12%,
respectively. Overall survival at 1, 6, 12, and 18 months was 91, 89,
86, and 86%, respectively.
Conclusions: The outcome after AVR in selected octogenarians is
excellent; the risks of surgery are acceptable and follow up of these
patients suggests satisfactory intermediate survival. Conventional
AVR in elderly patients with low to intermediate risk is a reasonable
option and should not be withheld on the basis of age alone.
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9. Initial Results of Concomitant LA MAZE with Open
Heart Surgery
Booth K, Dickson E, Jeganathan R, Jones M, Graham A
Royal Victoria Hospital, Belfast
Introduction: With a prevalence of 0.4% in the general population,
the presence of atrial fibrillation (AF) increases with age and with the
presence of heart disease [1]. AF is associated with an odds ratio for
death of 1.5 for men and 1.9 in women [2]. Ablation using discreet
field radiofrequency to isolate the pulmonary veins and resection of
the left atrial appendage is performed in our unit with concomitant
open heart procedures to treat patients with non-lone AF, as recom-
mended by national NICE guidelines [3].
Methods: All patients who underwent MAZE procedure with concom-
itant heart surgery between December 2004 and December 2009 were
retrospectively reviewed using computer records and patient charts.
Results: A total of 27 patients were identified with 20 female and 7
male and a median age of 67 (range 51–77). A range of concomitant
procedures included mitral and aortic valve surgery and coronary
artery bypass grafting (CABG), with the majority undergoing mitral
valve replacement (8 patients, 29.6%). 2 patients (7.4%) died in the
post-operative period and median follow up for the remaining 25
patients was 16 weeks (range 4–208). 100% of patients remained on
anti-arrhythmic medication and anti-coagulation for 3 months post-
operatively. Maintenance of sinus rhythm on follow up was recorded
in 16 patients (64%) prior to referral for DC cardioversion. 8 patients
were recorded as AF (32%) and two patients had permanent pace-
maker insertion (4%). 2 TIA’s were recorded with no post-operative
CVA’s. Further follow-up information is in progress currently with up
to date results of rhythm and medication status of these 25 patients.
Conclusion: In this series from our unit we have shown successful
restoration of sinus rhythm in 64% of patients who presented with con-
comitant heart disease requiring open heart surgery and suggest the MAZE
using radiofrequency ablation as a treatment strategy for these patients.
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10. What Does Brain Natriuretic Peptide Tell us About
Progressive Left Ventricular Diastolic Dysfunction?
Collier P, Waterhouse DF, Dawkins IR, Patle AK, Watson CJ,
Horgan S, Baugh JA, O’Hanlon R, Ledwidge MT, McDonald KM
St. Vincent’s University Hospital, Elm Park, Dublin
Background: Heart failure with preserved ejection fraction is com-
monly preceded by a prolonged asymptomatic phase during which
progressive left ventricular diastolic dysfunction (LVDD) develops.
The purpose of this study was to assess whether B-type natriuretic
peptide (BNP) could distinguish those with progressive LVDD from
those whose diastology remained stable.
Methods: This was a retrospective cohort substudy of the STOP-HF
trial [NCT00921960] an ongoing randomised controlled study
involving patients with risk factors for heart failure that are being
serially followed with clinical and echocardiographic assessment. We
defined LVDD progression using changes in left atrial volume index
(LAVI), a robust continuous echocardiographic measure of LVDD
whereby progressors had a LAVI increase of [3.5 ml/m2 from an
initial LAVI between 20 and 34 ml/m2. From 518 patients that
underwent serial clinical and echocardiographic assessment, 228
patients fulfilled these criteria and were included in the analysis.
Results: 34 (15%) patients displayed evidence of LVDD progression
and were compared to the remaining population. Mean follow up was
14 ± 5 months. At baseline, progressors were older (68 ± 8 vs.
65 ± 10 years; p \ 0.05), were more likely to be treated with beta-
blockers [17 (50%) vs. 49 (25%); p \ 0.05], had higher levels of BNP
[28 (14:44) vs. 17 (9:34); p \ 0.05] and had higher left ventricular
mass indices [105 ± 27 vs. 95 ± 23; p \ 0.05]. No significant gen-
der difference or difference in rates of hypertension, diabetes mellitus,
coronary artery disease, obesity or smoking was noted between
cohorts. Although BNP correlated with LAVI at both timepoint 1&2
(p \ 0.001), linear regression analysis revealed that even significant
increases in LAVI would anticipate just small increases in BNP of a
magnitude within biological variability.
Conclusions: Clinically, changes in BNP appear to be relatively indif-
ferent to LVDD progression and pronounced changes in LAVI. Given the
emerging epidemic of heart failure, more accurate biomarkers are urgently
needed to aid detection of those at high risk of LVDD progression.
11. Transcatheter Aortic Valve Implantation (TAVI)
in the Real World
Ni Dhonnchu T, Anwar A, Keenan N, Sugrue D, Hurley J
Mater Misericordiae University Hospital, Dublin
Introduction: Symptomatic Aortic Stenosis has a mortality of 50% at
1 year (PARTNER 2010). A significant proportion of these patients
are considered high/prohibitive risk for surgery. TAVI is an alterna-
tive treatment option in this patient group.
Objective: To outline our results in a single centre study over a
2-year period.
Methods: Nineteen patients with symptomatic aortic valve disease,
deemed non surgical candidates (following MDM discussion) for
surgery, were included in the study. These patients underwent TAVI
with the Edwards valve (Edwards Lifesciences) between November
2008 and September 2010.
Results. Mean age at implant was 81.47 years (±12.47). Mean logistic
EuroSCORE was 20% and mean STS score was 27.32%. Baseline
characteristics included coronary bypass grafting 47.37%, coronary
artery disease 42.10%, concomitant mitral valve disease 31.58% and
chronic kidney disease 42.11%. 78.95% of valves were inserted trans-
femorally while 21.05% were inserted transapically. Successful valve
deployment was observed in 100% with a 0% conversion to open surgery.
The incidence of coronary obstruction was 0% and valve embolization
was 5.3% (with successful subsequent redeployment). The mean peak
gradient was reduced from 84.38 to 21.75 mmHg. The aortic valve area
was increased from 0.7 to 1.6 cm2. Paravalvular leaks were classified as
none (15.79%), trivial (42.11%), mild (36.84%), moderate (5.3%) and
severe (0%). Postoperative complications included bleeding requiring re-
operation (0%), dialysis (5.3%), stroke (10.6%), tachyarrhythmias
(15.79%) and myocardial infarction (0%). 30 day mortality was 5.3%.
Patient NYHA status was reduced from 3.13 to 1.5.
Conclusions: TAVI IS associated with comparable mortality as
predicted by surgical risk calculators for the treatment of patients at
high/prohibitive surgical risk. Significant improvement in functional
status post procedure was also noted.
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12. A Novel Endovenous Approach for Treatment
of Massive Central Venous or Pulmonary Arterial
Thrombus, Mass, or Vegetation: The AngioVac Suction
Cannula and Circuit
Margey RJP, Sakhuja R, Gandhi S, Rogers RK, Weinberg I, Jaff MR,
Schainfeld R, Rosenfield K
Section of Vascular Medicine and Peripheral Intervention, Division of
Cardiology, Massachusetts General Hospital and Harvard Medical
School, Boston, USA
Introduction: Patients with right atrial, tricuspid valve, pulmonary
arterial and iliocaval thrombus, mass or vegetation are at risk for
significant short and long-term morbidity and mortality. Currently,
limited non-operative options are available for these patients. Optimal
management of these conditions remains uncertain. The AngioVac
suction cannula and circuit is a novel minimally-invasive endovenous
suction cannula aimed at removing ‘‘undesirable intravascular mate-
rial’’ (UIM) from the venous, right atrial, or pulmonary arterial system.
Methods: All patients with central venous and/or pulmonary arterial
and/or right atrial mass treated with the AngioVac cannula and circuit
were retrospectively evaluated. Procedural outcomes, including pro-
cedural success and procedural mortality, were evaluated. Procedural
success was defined by (1) removal of target pathology, (2) lack of
procedural complication and/or (3) in accordance with the goals of the
treating physician.
Results: A total of 40 cases have been performed. Mean age of the
cohort was 54.4 years with 57.5%:42.5% M:F ratio. 30% presented
with catheter-associated vegetation (25% of whom had co-existent
valvular vegetation), 37.5% presented with extensive iliocaval
thrombosis, and 32.5% presenting with massive or submassive PE.
Overall Procedural success was 75%, with the best outcomes for
iliocaval clot 93.3%, followed by catheter-associated vegetation
(83.3%; Valvular involvement 33%) and least favourable outcomes
for Pulmonary embolism 46.2%. 10% were converted to open oper-
ative procedures. There was one (2.5%) procedural death.
Conclusions: Early experience suggests that AngioVac device is a
possible alternative to surgical intervention, though atrial/ventricular
perforation represents rare but serious complications. In early cases,
the AngioVac appeared more effective for catheter-associated or non-
adherent right atrial or iliocaval UIM, than for pulmonary emboli,
especially in the distal main pulmonary arteries, and tricuspid valve
vegetations. These data suggest that procedural success may be
optimized by appropriate patient/pathology selection, ongoing
improvements in procedural processes and techniques, as well as
evolution of the device.
13. A 2-Year Audit of Organisms and Sensitivities
in Patients with Infective Endocarditis in a Quaternary
Referral Hospital
Graham C, O’Hare K, O’Connell B, Moloney G, Young V, Tolan M,
Daly C, Murphy R
St James’s Hospital, James’s Street, Dublin
Aims: To identify causative organisms and antibiotic sensitivities in
infective endocarditis (IE) patients in St James’s Hospital, Dublin
over a 2-year period.
Methods: Retrospective chart review, microbiological, pathological
and surgical database review of 47 patients with a diagnosis of IE
treated in St James’s Hospital between January 2009 and December
2010.
Results: The 47 patients identified were reviewed by a multidisci-
plinary team. Thirty-nine patients had native valve endocarditis, eight
had prosthetic valve endocarditis. There were six patients with a history
of IVDA. Surgery was performed in 23 (49%). Overall in-hospital
mortality was 19%. Twenty-four patients presented in 2009. Of these, 13
(54%) were culture negative, 6 (25%) were found to have staphylococ-
cus, 1 (4%) had streptococcus and 3 (12%) had enterococcus. The
streptococcus case identified was sensitive to penicillin. Of the six cases
of staphylococcus five (83%) were resistant to penicillin, two (33%) were
resistant to flucloxacillin and all were sensitive to gentamicin. In 2010
there were 23 cases of infective endocarditis. Fourteen (60%) were cul-
ture negative, four (17%) had staphylococcus, three (13%) had
streptococcus, one (4%) had enterococcus and three (13%) were caused
by other organisms. Again all streptococcus species isolated were sen-
sitive to penicillin. Of the six staphylococcus species isolated, four (60%)
were resistant to penicillin, four (60%) were resistant to flucloxacillin and
all were sensitive to gentamicin.
Conclusion: Mortality for index cases of IE in a quaternary referral centre
remains high. The most frequently identified organism was staphylococ-
cus with high rates of antibiotic resistance especially to penicillin.
14. Initial Experience of Primary PCI for ST Elevation
MI from the Perspective of a Non-PCI
Pal N, Byrne J, Charlton L, McClements B
Mater Hospital, Belfast Health and Social Care Trust, Belfast
Introduction: Primary PCI (PPCI) is the preferred revascularization
procedure for ST elevation myocardial infarction (STEMI) if the
procedure can be performed within 120 min after first medical contact
(FMC). For patients who present directly to an acute hospital without
PCI capability, rapid transfer to a PPCI centre is recommended pro-
vided time delays are not excessive. A PPCI service was launched in
Belfast in December 2009. This study assessed the feasibility of PPCI
as the treatment of choice for eligible patients presenting with STEMI
to the Mater Hospital, Belfast which does not have PCI facilities.
Patients: From the MINAP database 55 consecutive STEMI patients
were identified, who were transferred for PPCI. No patients received
lytic therapy for STEMI during this period. Initially ambulance ser-
vice protocols were not altered.
Results: 29 (53%) patients (Group 1) arrived by paramedic ambulance
and 26 (47%) (Group 2) self-referred to the Emergency Department (ED).
The median time from first FMC to first balloon inflation was longer in
Group 1 than Group 2 (120 vs. 100 min, p = 0.014). Only 51% of Group
1 patients achieved reperfusion within 120 min of FMC compared with
72% of Group 2 patients. There was no mortality in either group.
Conclusion: In the health care system in Belfast, PPCI is feasible and
safe as the default revascularization strategy for patients with STEMI
who present to a non-PCI capable acute hospital. However when
FMC is with a paramedic ambulance crew, transportation initially to
the local ED followed by inter-hospital transfer significantly length-
ens the time taken to achieve reperfusion. These data emphasize the
importance of maximizing the proportion of STEMI patients who are
transported directly to the PPCI centre. This is the focus of current
efforts in the Belfast PPCI Service.
15. A 24/7 Primary Percutaneous Coronary
Intervention Service




Introduction: Primary percutaneous coronary intervention (pPCI) is
the preferred treatment for ST elevation myocardial infarction
(STEMI) if a call-to-balloon (CTB) time \150 min can be achieved.
A 24/7 pPCI service was introduced in Belfast in December 2009.
Results: In the 13 month period from February 2010 to February 2011
a total of 236 patients activated the pPCI pathway. 70.8% were male
(mean age 61.5 years; range 30–99 years). 71% of cases presented
‘‘out of hours’’. Of the 236 patients, 24 (10%) were non-acute coronary
syndrome (ACS) and 9 patients had a non-STEMI. The remaining 203
patients had STEMI and 198 proceeded to pPCI. 5 STEMI patients did
not have pPCI (died before lab, age 99, distal disease, normal coro-
naries, coronary artery dissection). Analysis was performed on the 203
patients with STEMI. pPCI was performed via a radial approach in
85%, 93% had stent inserted (68% drug eluting), 79% had a glyco-
protein antagonist (Abciximab 97%) and an intra aortic ballon pump
was inserted in 12 cases (6%). In hospital mortality was 4.9%. In
patients with a first ECG diagnostic of STEMI 75% met the door-to-
balloon target of\90 min and 74% meet the CTB\150 min target. Of
patients admitted by the Northern Ireland Ambulance Service only
39% were brought directly to the catheterisation laboratory, 34% were
brought to the A&E department in the pPCI center and 27% were
brought to a non-pPCI A&E requiring a further transfer. The CTB
target was met respectively in 97, 50 and 25%.
Conclusion: A 24/7 pPCI service can be achieved with low mortality.
Admission through any A&E department adversely effects ability to
meet the CTB target.
16. Impact of Renal Insufficiency on Bleeding Events
in Patients Undergoing Percutaneous Coronary
Intervention
#Margey R, *Maree AO, Selzer F, *Adams B, *Patel N, Jneid H,
Marroquin OC, Mulukutla SR, §Laskey WK, *Jacobs AK
#Massachusetts General Hospital and Harvard Medical School,
Boston, MA, *Boston University School of Medicine, Boston
Medical Center, Boston, MA, Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, PA, Michael E. DeBakey VA
Medical Center and Baylor College of Medicine, Houston, TX,
§University of New Mexico School of Medicine, Albuquerque, NM
Background: Access site hematoma requiring blood transfusion
predicts mortality in patients undergoing PCI. Patients with renal insuf-
ficiency undergoing PCI have increased risk of adverse cardiovascular
events. However, little is known about the relationship between degrees
of renal insufficiency and bleeding in patients undergoing PCI.
Methods: This was a prospective, multi-center, cohort study of
consecutive patients undergoing PCI during three NHLBI Dynamic
Registry recruitment waves (2001–2006). In-hospital major and minor
bleeding events and access site bleeding requiring transfusion were
determined based on estimated glomerular filtration rate (eGFR). eGFR
was calculated using the MDRD equation (required serum creatinine,
age, race, gender). Statistical analysis comprised Kruskal–Wallis test,
Chi-square and Cochran–Mantel–Haenszel test for trend and multivari-
able logistic regression.
Results: Bleeding events and access site bleeding requiring transfusion
were significantly associated with renal insufficiency. Patients with renal
insufficiency were more commonly female (p\0.0001) and less likely to
receive peri- and post-procedural anticoagulation and antiplatelet therapy.
Among patients who survived to hospital discharge, those that bled or
required transfusion were significantly less likely to be discharged on a
thienopyridine (95.4 vs. 89.9; p \0.001 and 95.3 vs. 87.9; p = 0.005) but
not aspirin (96.3 vs. 96.2; p = 0.97 and 96.3 vs. 93.6; p = 0.29).
Conclusions: (1) Renal insufficiency predicts in-hospital bleeding
events in patients undergoing PCI; (2) even moderate levels of
impairment are associated with increased bleeding risk after adjust-
ment for all other measured variables; (3) patients undergoing PCI
who bleed are significantly more likely to have their clopidogrel
discontinued prior to discharge. Whether renal insufficiency imparts
added risk of mortality in patients who bleed and require blood
transfusion requires further study.












\45 (n = 661) 4.8 1.49 0.94–2.37 0.09
45–59 (n = 1,023) 5.1 1.58 1.06–2.36 0.03
60–74 (n = 1,544) 2.8 1.05 0.70–1.57 0.80
C75 (n = 2,822) 2.7 1.00 Reference n/a
Access site transfusion*
\45 (n = 661) 2.7 2.67 1.29–5.52 0.008
45–59 (n = 1,023) 1.5 1.41 0.67–2.99 0.37
60–74 (n = 1,544) 1.1 1.50 0.74–3.04 0.26
C75 (n = 2,822) 0.6 1.00 Reference n/a
Event rate comparisons (overall and trend): *p \ 0.001
The models were adjusted for the following factors: Bleeding: age,
sex, prior PCI, reason for revascularization, lesion complexity, can-
cer, procedural GP IIb/IIIa, procedural LMW heparin, post-PCI GP
IIb/IIIa and post-PCI heparin. Transfusions: age, sex, race, lesion
containing thrombus, no. of attempted lesions, ad-hoc PCI, attempted
total occlusion, cancer, procedural LMW heparin, procedural biva-
lirudin, and post-PCI heparin.
17. On-site Percutaneous Coronary Intervention (PCI)
at Altnagelvin Area Hospital has led to a Significant
Reduction in Time to PCI in Patients Presenting
with NSTEMI and Meets the ESC
Monaghan M, Small C, Hutchinson C, Armstrong E, Smart P, Hughes
S, Purvis J, McNeill A, McGlinchey P, Moore M
Altnagelvin Area Hospital, Londonderry
Background: The European Society of Cardiology (ESC) published
guidelines in 2010 on the management of patients presenting with
non-ST elevation MI (NSTEMI). They recommend that coronary
angiography and revascularisation should be performed during the
same hospital stay and preferably within 72 h of admission [1]. A
dedicated on-site PCI service was introduced in the Western Health
and Social Care Trust at Altnagelvin Area Hospital in February 2010
with emergency cardiac surgery support provided by the Belfast
Trust. Altnagelvin Hospital is a large District General Hospital and
had been performing on-site diagnostic cardiac catheterisation for
9 years. Prior to 2010, patients diagnosed with NSTEMI requiring
PCI were transferred to Belfast.
Aims: The aim of this pilot study was to investigate if introduction of an
on-site PCI service (1) is safe, (2) decreases time spent in hospital, (3)
reduces time to revascularisation as recommended by the ESC.
Results: A retrospective study was made comparing length of hospital
stay and time to revascularisation between a randomly selected cohort
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of patients (n = 23) who presented with NSTEMI in 2009 prior to
introduction off on-site PCI and patients (n = 45) who presented post
on-site PCI in 2010. The results are tabulated (Table 1). A significant
reduction in time to PCI from 7.54 days (±5.46) to 2.1 days (±1.4)
p = 0.009 was shown with a concomitant reduction in hospital stay
from 5.71 (±1.98) to 4.29 (2.62) p = 0.1. Survival to discharge and
90 days was 100%.
Conclusion: The establishment of on-site PCI is safe and has signifi-
cantly increased the proportion of patients receiving coronary







Patients (n) 23 45
Age (years) ± SD 61 ± 11 62 ± 13
Male, n (%) 15 (65%) 40 (89%)
Diabetes, n (%) 3 (13%) 7 (16%)
Smoking Hx, n (%) 16 (70%) 24 (53%)
HTN (n) 8 (35%) 20 (44%)
Chol [5 on admission, n (%) 8 (35%) 12 (27%)
Clinical heart failure, n (%) 1 (4.3%) 0
EF [30%, n (%) 17 (77%) 36 (100%)
Dynamic ECG changes, n (%) 11 (48%) 24 (53%)
LOS (nights) ± SD [excluding
inpatient CABG (n = 2)]
8.73 ± 10.28
(5.71 ± 1.98)
4.29 ± 2.62 0.05260.1
Time to catheterisation
(days) ± SD
3.22 ± 2.79 2.16 ± 1.20 0.0934
PCI performed, n (%) 11 (48%) 28 (62%)
Referred for CABG, n (%) 3 (13%) 2 (4%)
Referred for medical management,
n (%)
9 (40%) 15 (33%)
Days to PCI ± SD 7.54 ± 5.46 2.1 ± 1.4 0.0090
DES, n (%) 7/11 (64%) 19/28 (68%)
Radial access, n (%) 7/11 (64%) 15/45 (33%)
Alive to discharge, n (%) 22 (96%) 45 (100%)
Alive at 90 days, n (%) 22 (96%) 45 (100%)
Reference: 1. Guidelines on myocardial revascularization. The Task
Force on Myocardial Revascularisation of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic
Surgery (EACTS). Eur Heart J. (2010);31:2501–5.
18. Croi MyAction: First Results from an Innovative
Community-Based Vascular Prevention Programme
in Galway
1,2Flaherty G, 1Gibson I, 1Walsh AM, 1Kerins C, 4Connolly S,
1,3Crowley J
1Croi, West of Ireland Cardiac Foundation, 2National University of
Galway, Ireland, 3University Hospital Galway, 4Imperial College
Healthcare NHS Trust, London
Purpose: To investigate the impact of a community-based vascular
prevention programme (Croi MyAction) on medical and lifestyle
risk factors in patients at high risk of cardiovascular disease
(CVD).
Methods: Patients (heart SCORE C5%, Type 2 diabetes, peripheral
arterial disease) and their partners were invited to attend the 16-week
programme delivered by a multidisciplinary team (nurse, dietician,
physical activity specialist) in a community setting. Smoking and dietary
habits, physical activity levels, waist circumference and BMI, and
medical risk factors (blood pressure and lipids) were measured at the
initial assessment (IA) and at end of programme (EOP).
Results: Data on those who attended both IA and EOP were analysed
(Table 1). The mean age of patients was 55.1 years and the retention
rate on the programme was 89.7%.










Mean (SD) BMI (kg/m2) 32.8 (6.7) 31.4 (6.5)
p \ 0.001


















4.1 (2.2) 8.4 (2.4)
p \ 0.001
4.3 (2.1) 8.6 (2.4)
p \ 0.001
% Achieving physical activity
targets (C59/
week C 30 min)
9.3 63.2 p \ 0.001 19.4 61.2
p \ 0.001
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Conclusions: This study demonstrates that the MyAction vascular
prevention programme is acceptable to patients, with high adherence
rates and substantial improvements in both lifestyle and medical risk
factors for CVD.
19. Associations Between Findings on a Cardiac
Risk Assessment Questionnaire and Group 2 ECG
Abnormalities: Results from the West of Ireland
Screening for Sudden Cardiac Death in Young
People Study
Joyce E, Devenney D, Gargoum F, Nolan P, McGorrigan C, Crowley
J, Nash P, Daly K
Galway University Hospital, Galway
Introduction: Young people who participate in sport may have an
increased risk of sudden cardiac death (SCD). In Ireland, cardiac risk
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assessment using a questionnaire-based approach has been suggested.
We aimed to describe the association between findings on question-
naire and presence of ‘‘Group 2’’ ECG abnormalities, proposed as
markers of possible underlying cardiac pathology.
Methods: This was a prospective cross-sectional observational study.
A six-item questionnaire was developed. The population surveyed
consisted of young people aged 14–34 regularly engaged in sports of
at least moderate dynamic intensity. All participants had a physical
examination and a 12 lead ECG. Presence of Group 2 abnormalities
(T wave inversion, ST segment depression or pathological Q waves in
two or more leads; right/left axis deviation; right/left bundle branch
block; left atrial enlargement; right ventricular hypertrophy; pro-
longed/shortened QT interval; atrial/ventricular arrhythmias; delta or
epsilon waves; short PR interval or Brugada pattern) were noted.
Results: Between March and June 2009, 461 participants (70.7%
male, median age 19, 92% at least one high dynamic sport) completed
risk assessment. A ‘‘yes’’ answer to one or more questions (‘‘positive
questionnaire’’) occurred in 38.6%; the majority (87.1%) concerned
symptom related questions. Group 2 changes were noted in 28%.
These participants were not more likely to have provided a positive
versus a negative questionnaire (41.1 vs. 59%, p = 0.497). No
association occurred between these abnormalities and presence of
symptoms including syncope or a family history of premature SCD.
However personal history of a cardiac condition was independently
associated with a Group 2 ECG abnormality (OR 2.37, p = 0.029).
Conclusions: While over a third of participants returned positive
questionnaires only the question relating to personal history of cardiac
disease was associated with Group 2 ECG changes. Meanwhile, high
levels of these abnormalities were encountered in our screening
population, calling into question their use as surrogate markers of
possible cardiac pathology.
20. Non-Compliant Balloons for Final Kissing Inflation
in Coronary Bifurcation Lesions Treated
with Provisional T-Stenting: a Pilot Study
Mylotte D, Hovasse T, Ziani A, Lefevre T, Dumonteil N, Louvard Y,
Carrie D
Institut Cardiovasculaire Paris Sud, France
Objectives: To assess the procedural and long-term results of non-
compliant (NC) kissing balloon inflation (KBI) in patients undergoing
bifurcation intervention with the provisional side branch (SB) stenting
technique.
Background: Provisional SB stenting is the default strategy for
coronary bifurcation intervention. Recent data have suggested that
KBI with compliant balloons increases the risk of SB dissection and
restenosis. However, NC KBI may reduce SB complications.
Method: We prospectively enrolled patients undergoing provisional
SB stenting at two French centres. KBI was systematically performed
with NC balloons. Quantitative coronary angiography and digital
stent enhancement (DSE) were performed in all cases. Thirty-day and
1-year major adverse cardiac event (MACE) rates were assessed.
Results: We recruited 100 patients with a mean age of 67.3 ± 11.7
years. Diabetes mellitus was prevalent in 23%, renal dysfunction in 21%,
and multivessel disease in 69%. Intervention was performed for stable
angina in 48% and acute coronary syndromes in 27%. Target lesions were
the left main in 15% and the left anterior descending in 51%. The majority
of lesions (46%) were true-bifurcation stenoses (medina class: 1,1,1/
1,0,1/0,1,1). All lesions were successfully treated with NC KBI. SB
stenting was required in 6% (5 dissections, 1 residual stenosis). Using
DSE, a SB stent scaffold was evident in 89% following KBI. The
cumulative 12-month MACE rate was 4%. Target lesion revasculariza-
tion was required in 3%. No stent thrombosis occurred during follow-up.
Conclusions: Provisional SB stenting followed by NC KBI is asso-
ciated with high procedural success and low rates of clinical target
lesion failure.
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21. Efficacy and Safety of Transcatheter Aortic Valve
Implantation: Northern Ireland Experience
Manoharan G, Spence MS, Kodoth V, Maguire C, Anderson L,
Doherty R, Smith B, Glover P, Manoharan GB, Tomlin A, McKenna-
Maynard M, McAllister P, Gracey H, Dixon L, Johnston N
Royal Victoria Hospital, Grosvenor Road, Belfast
Introduction: Transcatheter aortic valve implantation (TAVI) is
increasingly being advocated for treating surgically inoperable or
high risk patients with severe symptomatic aortic stenosis. We started
our TAVI programme in February 2008 and report our findings using
the Medtronic CoreValve system in Northern Ireland.
Methods and Results: All patients who met the clinically and
technical criteria (annulus ranging from 19.5 to 27 mm; vascular
access C6 mm in diameter) were discussed and approved for the
procedure at a joint multidisciplinary meeting. Unless a patient
required a cut-down for vascular access, all cases were performed
under local anaesthesia and without sedation. All patients were
managed immediately post-procedure in the Coronary Care Unit.
A total of 85 patients (average age: 83 years old; average logistic
Euroscore: 25) were planned for TAVI to date. Procedural success
was 98% (1 procedural related mortality and the valve was not
delivered in 1 patient due to access difficulty), with 91.8% performed
under local anaesthesia. Percutaneous versus access cutdown (sub-
clavian or femoral artery) were 91.8 and 8.2%, respectively. TAVI
was performed for failing native aortic valve in 94.1% and biopros-
thetic valve (valve-in-valve) in 5.9% of patients. The 30-day, 6-month
and 1-year all cause mortality were 4.7, 7 and 11.6%, respectively.
Minor vascular access complication (by VARC definition) was 2.4%
(major = 0%). Clinical stroke was observed in X2 patients and gut
ischaemia presumed embolic event was observed in one patient: all
were in atrial fibrillation and were either unable to be prescribed
warfarin or had it stopped for another procedure.
Conclusions: In carefully pre-selected patients, TAVI performed by a
dedicated team is safe and efficacious. Performing the procedure
under local anaesthesia has merits. Pre-existence of untreated atrial
fibrillation correlates with increased risk of embolic events.
22. Initial Experience of a Mini Sternotomy Incision
in Aortic Valve Replacement
Beattie GW, Nzewi OC
Department of Cardiothoracic Surgery, Royal Victoria Hospital,
Belfast
Objective: In the past decade the quest to decrease the morbidity
from cardiothoracic surgery has led to the development of approaches
that avoids complete sternotomy incision. Utilising a mini sternotomy
gives good exposure to the ascending aorta. In some units this is the
standard approach to aortic valve surgery. Benefits include reduced
blood loss, lower post operative pain, a shorter time to extubation and




Methods: Data was retrieved from the national cardiac surgery
database and hospital records. A mini sternotomy is defined as an
upper midline incision of 5–7 cm, a sternotomy through the upper
sternum with extension through the third or fourth interspace laterally.
Results: 24 patients, 52% were female, a mean age 69 years (42–82).
Significant co-morbidities included diabetes (24%), COPD/asthma
(14%), previous CVA/TIA (14%), 29% of patients are grossly obese
and the mean logistic Euroscore was 7.19. There were no mortalities
or wound infections. One patient with pulmonary fibrosis was rein-
tubated and ventilated on the second postoperative day for 6 days.
Biological valves were used in 76% of patients. The mean cardio-
pulmonary bypass time was 127 min (SD 43) and cross clamp time
87 min (SD 24). Patients were ventilated on average 6 h (1–15) post
op and 29% received a blood transfusion. Median post operative stay
was 9 days (5–50). Two patients had a conversion to a full sternotomy
for bleeding.
Conclusions: Mini-sternotomy incision for aortic valve replacement
is safe and should be considered as a standard approach.
23. Atrial Septostomy for Severe Pulmonary Arterial
Hypertension: Evolving Percutaneous Approaches
Roy AK, McCullagh B, Gulam M, Nashat H, Adamali H, Gaine SP,
Walsh KP
Mater Misericordiae University Hospital, Dublin
Introduction: Atrial septostomy (AS) is often a palliative interven-
tion for patients with severe, refractory pulmonary arterial
hypertension (PAH), as it provides decompression of the failing right
ventricle, while also improving systemic cardiac output. Early use of
AS has been associated with improved survival. Successful outcomes
using graded balloon dilatation have been limited by high closure
rates and the need for recurrent procedures. We present a single centre
experience with novel approaches to AS, using either radiofrequency
perforation (RFP), cutting balloon dilatation, or insertion of butterfly
stents.
Methods: From 2005 to 2010, seven (n = 7) adult patients underwent
AS with transoesophageal echocardiography or ICE guidance. Tran-
septal access was obtained using either RFP, or standard
Brockenbrough needle technique. Cardiac haemodynamics were
measured throughout the procedure, with systemic oxygen saturation
targets of B10% decrease. Clinical follow-up was carried out via the
National Pulmonary Hypertension Unit. Three different techniques
were employed: (1) cutting balloon AS, (2) RFP of the interatrial
septum, or (3) butterfly stent insertion using a Cordis PG2910XD
10 9 29 mm stent with a preloaded 2.0 prolene suture to create a
narrowed stent waist upon deployment.
Results: The mean age was 55.1 years, with 42.9% (3/7) female and
mean (SD) pulmonary artery pressure 85.0 ± 23.2 mmHg. All
patients were NYHA IIIB-IV. AS method was RFP (n = 3/7), Cutting
Balloon (n = 3/7), and Butterfly stent one. There were no (0%)
procedural mortalities. The mean (SD) decrease of peripheral oxygen
saturations post-procedure was 7.29 ± 2.4%. In long term follow-up,
the mean survival was 2.8 years post AS, while five patients remain
alive (range from 1 to 7.3 years).
Conclusion: In a highly selected PAH cohort, AS is well tolerated,
and improves outcomes in addition to maximal medical therapy. Use
of the novel butterfly stent technique with ICE guidance may offer a
longer lasting AS alternative, and could be considered in PH patients
at an earlier stage in their disease, before irreversible right heart
failure and remodeling occurs.
24. Early Experience with the Watchman Left Atrial
Appendage Occluder Device
Neylon MA, Alqaseer M, Asgedom S, Morgan R, McAdam B, Sheahan
R, Foley D
Beaumont Hospital, Beaumont, Dublin
Atrial fibrillation is the most common cardiac arrhythmia and carries
with it the devastating complication of stroke. The left atrial
appendage (LAA) has been identified as the source of thrombi in over
90% of patients with non-valvular atrial fibrillation. Percutaneous
occlusion of the LAA with the Watchman device has been proven
non-inferior to warfarin therapy. We present our initial experience
with the Watchman device. We performed a prospective, observa-
tional single centre study in which LAA occlusion was performed in
35 patients between October 2009 and April 2011. Follow-up was
performed by means of transoesophageal echo, case notes review and
telephonic interview. 34 patients underwent successful device
placement. The procedure was performed via the right femoral vein;
using a 14 French dedicated delivery catheter; under conscious
sedation with fentanyl and midazolam. Devices were sized according
to maximal diameter and length of the LAA measured in four TOE
planes, to reach 20% compression post implantation. Mean procedure
time was 1 h. 78% of patients were male with a mean age of 73 (range
63–85 years). The indications for device placement are shown in
Table 1. Average CHADS2 score was 2.7 (2–5). The anticoagulation
strategy for at least 6 weeks post implantation was either full war-
farinization for those already on warfarin (2), dabigatran 110 mg bd
(19), 150 mg bd (8) or 75 mg bd (1). 4 patients who experienced
significant bleeding on warfarin were prescribed dual antiplatelet
therapy post implant. 95% of patients were discharged the same day.
There were no major adverse cardiac or cerebrovascular complica-
tions associated with device implantation. 1 patient required repeat
hospitalisation 2 days after implant with a large groin haematoma. 1
patient has transient arrhythmia that settled on medical treatment and
there were no cases of pericardial effusion. During follow-up TOE,
four patients were noted to have echodense material attached to the
device—considered to represent thrombus and thus were put on
150 mg bid dabigatran for a further 4–6 weeks with TOE thereafter.
There were no clinical neurological events in these patients in follow
up and all resolved on follow up TOE. For all patients during follow-
up ranging from 2 to 18 months no ischemic strokes or embolic
events have occurred. Early single centre experience with percuta-
neous LAA occlusion with the Watchman device shows that the
procedure is feasible and safe in experienced hands. No cerebral
events have been observed thus far but early phase anticoagulation
appears important. TOE is central to patient selection, per procedural









25. 25 years of Adult ECMO in Ireland: The History,
Development and Results of the Service from 1985
to 2010
Regan R
Department of Perfusion Prof. Eoin O’Malley National Centre for
Cardiothoracic Surgery, Mater Misericordiae University Hospital,
Dublin
Extracorporeal Life Support (ECLS) is a term used to describe pro-
longed but temporary support (usually 1–30 days) of heart and/or lung
function using mechanical devices. Two forms of ECLS are Extra
Corporeal Membrane Oxygenation (ECMO) and short-term Mechan-
ical Circulatory Support (MCS). ECMO provides support for patients
with reversible respiratory dysfunction using veno-venous ECMO
(VV ECMO) and support for cardio/respiratory dysfunction using
veno-arterial ECMO (VA ECMO). It is indicated for pre-operative
stabilisation, investigation, resuscitation, post-operative support, as a
bridge to transplantation or for cardiogenic shock that is refractory to
conventional therapies. The first utilisation of ECMO was on the first
heart transplant performed in this country in 1985 on post-op day 74,
following acute rejection. In these early pioneering days of trans-
plantation the use of ECMO was only reserved as a ‘‘last ditch’’ effort
to try and salvage life. Since 1985 the Mater Misericordiae University
Hospital (MMUH) has supported 41 patients, 13 female and 27 male
with an age profile of 16–65 years. Of these, 37 received ECMO
support and 4 received short-term MCS support. All 37 ECMO
patients were supported using VA ECMO for post-operative fulminant
cardiac failure and a combination of VV-VA ECMO for respiratory
support. Exactly half of all VA ECMO cases (12 patients) were for
post-transplant support with the remaining caseload (50%) a mix of
post-cardiotomy surgeries. A variety of mechanical devices were used
for ECMO support that will be described, in addition to the latest
current technology for ECMO now being used in our institution. The
survival rate for all VA ECMO patients in the MMUH is 30%. In 2009,
following the A (H1N1) pandemic, the formal development of an adult
respiratory ECMO programme began with the establishment of an
ECMO director to lead the new development. To date 13 patients have
been supported with ECMO for respiratory failure with a cumulative
run time of 432 days and with the longest successful VV support
duration being 60 days with an overall survival rate of 69%.
26. Actual Versus Predicted Post Ventricular Assist
Device Outcomes in A Mixed Device Group:
a Retrospective Study From The National Cardiac
Transplant Centre
Joyce E, Doherty M, Buckley U, Anwar A, Ni Dhonnchu T, Kinsella
A, Healy D, Wood AE, Nolke L, McCarthy J, Mahon N
Mater Misericordiae University Hospital, Eccles Street, Dublin
Introduction: Ventricular assist device (VAD) therapy has a growing
role in the management of advanced heart failure. Preoperative
scoring systems including the Lietz score and the Right Ventricular
Failure Risk Score (RVFRS) have been validated for older pulsatile
flow devices. Our aim was to evaluate concordance between predicted
and actual outcomes in patients receiving either pulsatile (Thoratec
paracorporeal:PVAD) or newer axial flow devices (Heartmate II).
Methods: All patients with a left ventricular assist device (LVAD) or
biventricular assist device (BiVAD) were retrospectively included.
Lietz and RVFRS scores, incorporating markers of nutrition and of
renal, liver, bone marrow and right ventricular dysfunction were
recorded. Patients were divided into risk categories reflecting
probability of in-hospital and 1-year mortality (Lietz score) or right
ventricular failure and 1-year mortality (RVFRS). Endpoints were
survival to discharge on VAD therapy or cardiac transplantation or
occurrence of one or more major complication (stroke, sepsis, major
bleeding, device complication, acute renal failure).
Results: 15 patients (mean age 41.9, 73.3% non-ischemic, 86.7%
bridge-to-transplant) underwent VAD placement (9 PVAD and 6
Heartmate II) between April 2005 and January 2011. 73.3% were
alive to discharge or transplant. Three of the four deaths occurred
in the paracorporeal device group—Lietz score predicted high/very
high risk in all 3. Of ten patients (7 PVAD vs. 3 Heartmate II) who
experienced at least one major complication, Lietz score predicted
at least medium risk in six. Among Heartmate II recipients, Lietz
score suggested high risk in one and medium in three. Only 1 of
the 12 LVAD patients with a low RVFRS score developed RV
failure.
Conclusions: RVFRS had an excellent negative predictive accuracy
for RV failure in our population. Survival in Heartmate II recipients
was good, even when Lietz score indicated increased risk, suggesting
this type of device be preferred when the risk of RV failure is low.
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27. The Early Role of CMR in the Assessment
of Cardiomyopathy
Barrett M, Waterhouse DF, Morgan RB, Molloy E, Sheahan R,
McAdam B, Gumbrielle T, Foley D, O’Hanlon R
Cardiac MRI Unit, Blackrock Clinic, Blackrock, Co. Dublin
Introduction: Investigation and risk stratification of suspected or
confirmed cardiomyopathy traditionally involves correlation between
electrocardiographic, echocardiographic and angiographic findings in
an appropriate clinical setting. Cardiac magnetic resonance (CMR) is
the new gold standard in assessment of cardiac structure, function and
perfusion, provided in a single study. Aetiology and prognostic fac-
tors may be investigated concurrently.
Methods: This was a single centre, 12-month experience of patients
referred for assessment of presumptive cardiomyopathy.
Results: 224 patients (145 male, 79 female) underwent CMR
assessment of cardiomyopathy. 177 (79%) were outpatient referrals.
Prior to CMR, 97 patients (43.3%) had a transthoracic echocardio-
gram. 43 (19.2%) had an angiogram, 35 (15.6%) had an abnormal
holter monitor and 64 (28.6%) had ECG changes. The primary
indications for CMR included: 59 (26.3%)—arrhythmia; 37
(16.5%)—cardiac symptoms with normal coronaries; 32 (14.3%)—
screening for family history of CM/SCD; 19 (8.5%)— follow-up of
previously diagnosed CM. CMR provided sufficient information to
confirm or outrule cardiomyopathy in 68.2% of cases. A new diag-
nosis of cardiomyopathy was made in 39.9%. CMR also had an
important role in ongoing assessment of patients with established
diagnosis of cardiomyopathy, with 31.6% having their previous
diagnosis outruled and 47.4% being recommended for device
implantation as a direct result of CMR findings. Overall in cardio-
myopathy assessment, CMR had an impact on management in 50.2%
of patients, with a therapeutic consequence on 36.3%, including
medication changes in 26.9%.
Conclusion: Patients at all stages of the clinical spectrum of car-
diomyopathy, from initial presentation to institution of therapy and
long-term follow up may benefit from CMR.
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28. Cardiac MRI Findings in Hypertrophic
Cardiomyopathy: a Northern Ireland Population
1Lyons K, 2Dixon L, 2Johnston N, 3Horan P
1Belfast City Hospital, 2Royal Victoria Hospital, 3Antrim Area
Hospital
Cardiac magnetic resonance imaging (CMR) is increasingly used in the
diagnosis and risk stratification of hypertrophic cardiomyopathy
(HCM) providing additional anatomical and functional information. It
also identifies myocardial fibrosis using delayed gadolinium
enhancement (DGE) which is an independent adverse prognostic factor
for sudden cardiac death (SCD) [1]. We retrospectively analysed all
CMRs diagnostic of HCM during 2010, evaluating demographic fea-
tures, LV mass, resting LVOT gradient and prevalence of systolic
anterior motion (SAM) of the mitral valve and myocardial fibrosis. 62
patients had CMR findings consistent with HCM. 42 (67.7%) patients
were male and mean age was 55.7 years. 25 males and 11 females had
indexed LV mass above the normal range. Mean LV ejection fraction
was 69.3%. 16 (25.8%) patients had SAM and 11 (17.7%) had elevated
resting LVOT gradients, all with associated asymmetric septal hyper-
trophy. Hypertrophy was predominantly asymmetric in 50 (80.6%)
apical in 9 (14.5%) and concentric in 3 (4.9%) patients. 61 patients
received contrast and 41 (67%) had significant DGE. There was no
significant difference in prevalence of DGE based on gender
(p = 0.079) or patient age (p = 0.34). DGE was more common in
apical (88.9%) compared with septal hypertrophy (67.3%). Indexed LV
mass was greater in the DGE group [mean 85.4 g (SD 20.1) vs. mean
77.4 g (SD 19.4)]; this was not statistically significant (p = 0.15). LV
ejection fraction was lower in the DGE group [mean 68.1% (SD 6.6) vs.
mean 71.5% (SD 6.9)] but again this difference was not statistically
significant (p = 0.07). CMR findings in patients with HCM in Northern
Ireland are similar to those reported in Europe and the USA [2]; the
majority have asymmetric septal hypertrophy and a significant pro-
portion have DGE, an increasingly recognised predictor of SCD.
Further studies in this population will determine the link between DGE
and other traditional risk factors for SCD.
Reference
O’Hanlon R, Grasson A, Roughton M et al. Prognostic significance of
myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll
Cardiol. 2010;56:867–74.
29. Atrial and Ventricular Functional Changes
on Echocardiography in Newly Diagnosed Untreated
Hereditary Haemochromatosis
Almuntaser I, King G, Norris S, Daly C, Ellis E, Murphy R
Departments of Cardiology and Hepatology, St James’s Hospital,
Dublin
Background and Objectives: Hereditary haemochromatosis (HH)
may be associated with infiltrative cardiomyopathy and atrial
arrhythmias. Doppler echocardiogram derived left atrial parameters
including the left atrial ejection force (LAEF) were used to evaluate
left atrial (LA) systolic function. The relationship between this LAEF
and left ventricular (LV) function was investigated.
Methods: Fourteen subjects with newly diagnosed untreated HH
(mean age 46.92 ± 2.6) and 14 age and gender matched control
subjects (mean age 40.23 ± 3.2) were recruited and underwent
echocardiography with comprehensive systolic and diastolic func-
tional evaluation. Left and right ventricular (LV and RV) myocardial
strain (MS) was measured. The LV and right ventricular (RV) myo-
cardial performance indexes (MPI), the transit time of the left atrial
pressure wave A-Ar interval were measured. Left atrial ejection force,
defined as 1/3 9 mitral valve area (MVA) 9 A2 (where A is the atrial
flow velocity of transmitral Doppler).
Results: In subjects with HH, LAEF was lower (136.27 ± 7.4%) than
control (202.9 ± 7.4%, P \ 0.001). The peak isovolumic acceleration
recorded at the free wall of LV and RV was lower in the HH compared
to controls (P [ 0.0001). The LV and RV MS, A-Ar, and tissue
Doppler (TD) E0 were reduced in HH subjects compared to controls
(P [ 0.001). Moreover, the MPI of LV and RV was greater in HH
subjects than controls (P \ 0.01). Significant correlation was observed
between LAEF and A-Ar, TD E0, TD Sm systolic velocity, and LV
MPI (r = 0.92, 0.89, 0.71, -0.71 and P \ 0.0001, respectively). In a
stepwise regression model, TD E0 (P = 0.006), emerged as the only
independent determinant of LAEF (R2 = 0.86, P \ 0.0001).
Conclusion: Left atrial ejection force is a novel non-invasive
parameter of LA systolic function and demonstrates the close inter-
play between LA and LV function in subjects with HH. The additive
clinical value of assessing LA systolic function needs further study.
30. Is There a Mortality Risk Associated with Aspirin
use in Heart Failure? Results from a Large Community
Based Cohort
1,2Bermingham M, 1Shanahan MK, 1Miwa S, 1Dawkins I, 1O’Hanlon
R, 1,2McDonald K, 1,2Ledwidge M
1Heart Failure Unit, St Vincent’s University Hospital, 2School of
Medicine and Medical Science, University College Dublin
Background: The use of aspirin therapy in heart failure (HF) is
controversial. There is contradictory evidence on the impact of aspirin
on attenuation of ACE inhibitor benefits and several studies have
suggested an adverse impact on morbidity in this setting. This ret-
rospective study evaluated the association of aspirin therapy with
mortality in a HF cohort with long-term follow-up.
Methods: This is a retrospective cohort study of patients attending a
HF Disease Management Programme. Chart review confirmed aspirin
prescription, dose and duration of use. The primary endpoint was the
association with mortality of aspirin compared to no aspirin over
long-term follow-up using unadjusted and adjusted Cox-proportional
hazards modelling with Kaplan–Meier survival curves.
Results: Data were available for 1,278 patients. Mean population age
was 70.2 ± 12.3 years, 64% of patients were male and mean follow-
up time was 3.1 ± 2.5 years. Aspirin was used by 769 (60.2%)
patients and 607 of these (78.9%) used aspirin for their entire follow-
up. The average aspirin dose was 89.5 ± 53.4 mg. Aspirin users were
older than non aspirin users, had greater rates of coronary artery
disease, myocardial infarction, angina, dyslipidaemia (all p \ 0.001),
diabetes mellitus (p = 0.01), hypertension (p = 0.03), a lower rate of
atrial fibrillation (p \ 0.001) and had higher lnBNP (p = 0.001).
Aspirin users were more likely to be prescribed statins and less likely
to be prescribed warfarin (both p \ 0.001). In the total population, 440
(34.4%) patients died over the follow-up period. In unadjusted analysis
there was no difference in mortality between aspirin users and non-
users (33.2 vs. 36.3%, p = 0.241). However, when fully adjusted for
age, sex, comorbidities, other medications and BNP, aspirin use
showed a 30.3% survival benefit compared to no aspirin use in this
community HF population (HR 0.697, 95% CI 0.507–0.958,
p = 0.027).
Conclusion: This retrospective evaluation of low-dose aspirin therapy
in HF patients with long term follow-up shows an association with
mortality benefit when adjusted for key population differences
including BNP. Randomised, prospective studies are required to
clarify the role of aspirin therapy in HF.
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31. Detection of High Sensitivity TNT Using Fourth
Generation Immunoassay in Pulmonary Hypertension
Patients Identifies a Subgroup with More Advanced
Disease
Roy AK, McCullagh B, McGorrian C, Russell C, Fitzgibbon M,
Murray PT, Gaine SP
Mater Misericordiae Hospital, Dublin
Purpose: Circulating cardiac troponin T (TNT) is a marker for
subendocardial ischaemia and alteration of structural proteins in
the myocardium. Using a third generation Roche assay, cardiac
TNT is an independent marker of increased mortality in chronic
pulmonary arterial hypertension (PAH) patients. We examine the
association between the new fourth generation Roche assay for
high sensitivity TNT (hsTNT) and markers of disease state in
PAH.
Methods: The study population consisted of 104 patients with
chronic stable PH (WHO ClassII and III). High sensitivity TnT
(hsTNT) was measured in patients’ serum, using Roche Elecsys
electrochemiluminescence immunoassay (ECLIA), with a detection
limit of 3 ng/L, and 99th percentile upper reference limit of 14 ng/L
(‘‘positive’’ hsTNT). Clinical and laboratory parameters, including
6 min-walk test (6MWT), cardiac hemodynamic (mPAP, PVR),
serum Neutrophil Gelatinase-Associated Lipocalin (NGAL), BNP
(ELISA, Bachem) and Troponin I (ARCHITECT, Abbott) were also
measured, and compared by hsTNT status using the Student’s t test
and the Mann–Whitney U test.
Results: The etiology of PH was (i) PAH associated with con-
nective tissue disease (38.5%) (ii) idiopathic PAH (34.6%) and (iii)
chronic thromboembolic PH (Not PAH) (24.3%). Positive hsTNT
was detected in 31.7% of PAH patients. Positive hsTNT was sig-
nificantly associated with older age, reduced distance on 6MWT,
and increased serum NGAL (Table 1). In a linear regression model,
hsTNT levels were positively correlated with 6MWT (r = -0.54,
p \ 0.001).
Conclusion: Chronic PH patients with detectable hsTNT [99th
percentile have clinical parameters suggestive of more advanced
disease. Routine assessment of hsTNT in the outpatient setting may
contribute to therapeutic goal setting in PH. It remains to be deter-
mined whether hsTNT changes in conjunction with favourable
treatment responses.
Table 1 Comparison of clinical features by high-sensitivity troponin










Age (years): mean (SD) 51.9 (15.4) 64.3 (12.1) t = -4.0 \0.001
NGAL (ng/mL): median
(IQR)*
193 (89) 226 (157) z = -2.6 0.01
6MWT in metres:
mean (SD)
399.5 (137.4) 337.4 (14.2) t = 5.11 \0.001
Pulmonary artery pressure
(mmHg): mean (SD)




5.5 (6.7) 4.6 (8.8) z = 0.027 0.97
BNP (pg/mL): median (IQR) 79 (187) 279 (277) z = -1.95 0.051
* IQR Interquartile Range
32. Does Right Ventricular Function Alone Predict
Outcomes After CRT? An Analysis of the MADIT-CRT
Population
Campbell P, Takeuchi M, l Bourgoun M, Foster E, Brown MW, Moss
AJ, Pfeffer MA, Solomon SD
Brigham and Women’s Hospital, Boston, Mass. USA
Background: Right ventricular (RV) dysfunction is associated with
worse outcomes after CRT. We have shown that patients in the
MADIT-CRT trial with the best RV function after 1 year demon-
strated the lowest subsequent event rates. However, we sought to
determine if this was related to improvement in LV function.
Methods: 1,820 patients were randomly assigned to CRT plus ICD
(CRT-D) or ICD only in a 3:2 ratio. We assessed RV function as right
ventricular fractional area change (RVFAC) by echocardiography.
RVFAC at baseline (n = 1,511) and 1 year (n = 1,273) was asses-
sed, and change in RVFAC calculated (n = 1,126).
Results: Patients were divided into groups above and below the
median of achieved RVFAC and LVEF at 1 year and a landmark
analysis was performed to assess subsequent event rates. Those with
the worst RV and LV function at 1 year had the highest event rates,
while those with the best biventricular function had the lowest event
rates (primary event rate 16.9 vs. 6% per year). Every 5% absolute
increase in RVFAC from baseline was associated with a 20% reduc-
tion in risk of subsequent primary outcome (HR 0.8; 95% CI 0.66,
0.97; p = 0.019). However when adjusted for change in LVEF over
the same period, RV function was no longer an independent predictor
of outcome (HR 0.93; 95% CI 0.75, 1.15; p = 0.513).
Conclusions: Patients with the best biventricular function at 1 year
have the lowest subsequent event rates. Improvement in RV function
as a predictor of outcome was not independent of improvement in LV
function, suggesting that RV improvement occurs as a consequence of
improvement in LV function.
Poster Presentations
33. Comparison of Traditional and Novel Definitions
of Acute Kidney Injury for the Prediction of Outcomes
in Acute De-Compensated Heart Failure
Roy AK, McGorrian C, Nashat H, Tracey C, Kavanaugh E, Brennan
A, Maksudova N, Mahon NG, Murray PT
Mater Misericordiae University Hospital, Dublin
Acute Kidney Injury (AKI) has a major impact on prognosis in acute
decompensated heart failure (ADHF). Several definitions of AKI have
recently been proposed, with little or no validation in ADHF. This
study compares the ability of worsening renal function (WRF) with
several novel AKI definitions (the kidney disease: improving global
outcomes (KDIGO), RIFLE, and AKIN classifications) to detect and
stage AKI, and to predict major clinical outcomes at 30 days and
1 year.
Methods: Analysis was performed on prospective data collected from
811 patients with ADHF admissions with 30-day, and 1-year event
(composite of death, HF readmission, and dialysis) follow-up. The
incidence, stages, and outcomes of AKI were determined using four
definitions (KDIGO, RIFLE, AKIN, and WRF; see Table), and
compared using ROC analysis.
Results: Complete data was available for N = 646 patients, with
mean age 64.6 ± 14.4 years, and 70.6% male. AKI by any definition
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occurred in 39.9% (258). AKI was associated with increased inci-
dence of the primary outcome at 30-days (31.4 vs. 6.4%, v2 = 70.3
and p \ 0.001) and 1-year (65.5 vs. 29.1%, v2 = 83.4 and
p \ 0.001).There was a stepwise increase in the incidence of the
30-day and 1-year primary outcomes with increasing AKI stages
using any criteria (p \ 0.001). In direct comparison, KDIGO showed
better predictive ability than WRF for the 30-day- (AUC 0.75 vs.
0.72, v2 = 5.6; p = 0.02) and 1-year primary outcome (AUC 0.67 vs.
0.65, v2 = 4.8; p = 0.03). RIFLE also had superior predictive ability
for the 30-day outcome (see Table 1).
Conclusion: AKI cases identified by the KDIGO and RIFLE systems
are associated with more adverse outcomes at 30-days, when com-
pared to WRF- or AKIN-defined cases. The KDIGO and RIFLE
criteria show better AUC for prediction of adverse outcomes, sug-
gesting that clinically meaningful changes in serum creatinine during
admission for ADHF may be better identified using these newer
diagnostic criteria for AKI.

























































































a Area under the receiver operating curve
b 95% confidence interval
34. Biological Variability of Bioelectrical Impedance
Testing in a Cardiac Inpatient Setting
Mak G, Murtagh G, O’Connell R, Dawkins I, O’Hanlon R, Ledwidge
M, McDonald K
St. Vincent’s University Hospital, Dublin
Purpose: Bioelectrical impedance is a relatively new modality used
to noninvasively measure fluid accumulation in the setting of heart
failure. The variability of measurements in bioelectrical impedance
analysis has yet to be described extensively in literature. This study
aims to describe the biological variability of bioimpedance readings
in an inpatient setting.
Methods: The study has been approved by the local ethics committee
and is currently being conducted at St Vincent’s University Hospital,
Dublin. It is intended to recruit 100 inpatients with either heart failure
or acute coronary syndrome. The data currently presented are taken
from an interim analysis of the study. After informed consent, total
body impedance readings [which includes hydration (H), resistance
(Rz) and reactance (Xc)] were measured from the right dorsal wrist
and ipsilateral ankle of the patient (carried out by investigator 1). A
repeat measurement was taken 5 min later on both the right and left
side of the body by the same investigator. A second investigator
would subsequently repeat the measurement 5 min later from the
right side of the body. Data analysis was performed using SPSS
(Version 13).
Results: To date, 40 patients have been recruited, 26 were male and
the mean age was 67.8 ± 11.7 years. Eighteen patients (45%) had a
history of heart failure. Interobserver variabilities (i.e. the variability
of measurements from two different investigators) were 1.0 ± 1.7,
5.0 ± 4.6 and 9.0 ± 15.9% for H, Rz and Xc, respectively. Intraob-
server variabilities (i.e. the variability of measurements from one
investigator) for H, Rz and Xc were 0.8 ± 1.5, 2.3 ± 3.4 and
7.5 ± 12.2%, respectively. The intrapositional variabilities (i.e. the
variability of measurements taken from either the left and right side of
the body) of H, Rz and Xc were 1.4 ± 2.5, 6.0 ± 5.7 and
9.9 ± 9.3%, respectively.
Conclusion: Bioelectrical impedance demonstrates little interob-
server, intraobserver and intrapositional variability and may be a
reliable and consistent measure of fluid overload in a heart failure
setting.
35. Screening for Asymptomatic Left Ventricular
Dysfunction Using B-Type Natriuretic Peptide: Effect
of Left Ventricular Diastolic Dysfunction on Results:
a Report from the STOP-HF Study
Murtagh G, Dawkins IR, Ledwidge MT, Tallon E, O’ Hanlon R,
McDonald KM
St Vincent’s University Hospital, Heart Failure Unit, Dublin
Purpose: BNP has been subject to concerns regarding false positive
rates when used as a screening tool for asymptomatic left ventricular
dysfunction. Left atrial volume index (LAVI) is elevated in patients
with left ventricular diastolic dysfunction (LVDD). It is increasingly
being recognised that LVDD is associated with similar rates of
morbidity and mortality. We sought to determine whether LVDD was
responsible for abnormalities in BNP readings leading to ‘‘false’’
positive BNP results.
Methods: The STOP-HF project involves a population of high car-
diovascular risk patients who underwent electrocardiography,
echocardiography and BNP sampling. For this study, 827 patients
were analysed. We selected those patients with an ejection fraction of
C50%, but a BNP of (a) over 50 pg/mL, and (b) over 100 pg/mL, and
analysed the LAVI in both groups to determine if indices for LVDD
were present in this population.
Results: There were 191 patients with EF C50% and BNP over
50 pg/mL (group a). This would correspond to a false positive rate
of 23% for a BNP cutoff level of 50 pg/mL. However 98 of these
patients (51.3%) had a LAVI [32 mL/m2. 77 of 827 patients
analysed had a BNP level of over 100 pg/mL but an EF C50%,
giving a false positive rate of 9%. Of these, 54 (70.1%) had a
LAVI [32 mL/m2. Hence, if we regard LV dysfunction as mean-
ing either LVSD or LVDD, 11% of patients were in fact false
positives at a cutoff of 100 pg/mL, and only 3% at a cutoff of
50 pg/mL.
Conclusion: A significant proportion of patients with normal left
ventricular systolic function, but elevated BNP levels, display evi-
dence of LVDD as indicated by a LAVI [32 mL/m2.
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36. B-Type Natriuretic Peptide Response with Peak
Exercise and Symptom Reproduction in Determining
Heart Failure Diagnosis in a New Diagnostic Heart
Failure Clinic: Interim Analysis
Voon KJ, Murtagh G, Badabhagni M, Patle A, Ledwidge MT,
O’Hanlon R, McDonald KM
St. Vincent’s University Hospital, Dublin
Purpose: The diagnosis of heart failure (HF) can be challenging.
Symptoms may be non-specific, examination unremarkable and
B-type natriuretic peptide (BNP) levels may be inconclusive. In
such circumstances, the presence of structural/functional abnor-
mality on Doppler-echocardiography may indicate, but does not
confirm HF. We sought to examine the role of BNP response to
peak exercise in the evaluation of HF diagnosis in this uncertain
group.
Methods: We have embarked on a prospective randomized
study to assess BNP response to exercise in 90 patients with
proven HF (n = 30), non-HF (n = 30) and a group of patients with
indeterminate presentation (diagnosis of HF unclear, n = 30) as
determined by two heart failure cardiologists. Patients with sus-
pected HF referred to our dedicated new diagnostic HF clinic
undergo clinical assessment, ECG, resting BNP and echocardiog-
raphy. A modified walk test is performed until peak exercise at
minimum BORG 3 dyspnoea. BNP levels and Doppler-echocardi-
ography was obtained in each patient using standard techniques at
baseline, peak-exercise and 30 min post-exercise. Results were
expressed as mean ± SD.
Results: In this ongoing study, we have to date assessed 36 patients
(age 75 ± 6.7 years, male 56%). Results show a change in pre- and
peak-exercise BNP levels in HF versus non-HF of 72.7 ± 101.5
versus 7.1 ± 4.7 pg/mL. HF patients also demonstrated an increase in
lateral wall E/E0 compared with non-HF group (0.5 ± 3.2 vs. -
2.2 ± 1.3). Four of eight indeterminate patients have demonstrated a
pattern similar to HF patients.
Conclusion: As expected, the initial experience in this ongoing study
has demonstrated a different trend in exercise-induced changes in
BNP and E/E0 between HF and non-HF patients. Within the inde-
terminate group, two distinct patterns are developing which may help
provide a more precise diagnosis to this group.
37. Undertreatment of Asymptomatic Left Ventricular
Dysfunction: a Report from the STOP-HF Study
Murtagh G, Dawkins IR, Ledwidge MT, Tallon E, O’ Hanlon R,
McDonald KM
St Vincent’s University Hospital, Heart Failure Unit, Dublin
Purpose: Although several potential screening tools for heart failure
have been discredited owing to suboptimal diagnostic performance, it
has also been hypothesised that those with ALVSD are already on
effective preventative treatment, thereby minimising the impact of a
formal screening programme. The purpose of this report was to
determine what percentage of patients shown to have ALVSD were
prescribed therapies known to protect against progressive ventricular
dysfunction at the time of diagnosis.
Methods: The STOP-HF program presently involves 1,400 high
cardiovascular risk individuals with risk factors for heart failure who
were screened for ALVSD by electrocardiography, B-type natriuretic
peptide (BNP) sampling and Doppler-echocardiography performed.
We analysed the patient demographics among those with an left
ventricular ejection fraction (EF) of \40%, and \50%, and deter-
mined what medication had been prescribed.
Results: Of the 991 patients studied to date, 52 (5%) had an EF
\50% with a mean age of 65 years. Forty-one of these (79%) were
male). More pronounced LVSD, as demonstrated by an EF \40%,
was found in 15 of the total population of 991 subjects (2%).
Analysis of medication use demonstrated that ACEI/ARB was not
being prescribed in 32% of patients with a LVEF \50 and 34% in
those with a LVEF \40%. The majority of patients receiving these
agents were not on clinical trial doses. Beta blockers were not
prescribed in 52% of patients with LVEF \50%, and 60% of those
with LVEF \40%.
Conclusion: It is clear that there is significant undertreatment and
underdosing of this group in terms of therapies shown to protect
ventricular function. This observation underlines the need to screen
for this group.
38. The Benefits of the Use of Chronic
Phosphodiesterase 5 Inhibitors (PDE5) in Patients
with Heart Failure with Reduced Ejection Fraction
and Secondary Pulmonary Hypertension: a Single
Center Study
Al Qaseer M, Raleigh C, Egan S, Brendan McAdam
Beaumont Hospital, Beaumont, Dublin
Background: Despite the substantial pre-clinical evidence that veri-
fies the benefit of PDE5 inhibition in the management of heart failure,
there are only limited short-term trials that have been conducted
which confirm those results in the human trials.
Methods: This is retrospective observational study from the sup-
portive heart failure unit in Beaumont Hospital, Ireland. We looked at
a cohort of patients with heart failure and reduced ejection fraction
(caused by different etiologies) with secondary pulmonary hyper-
tension that have refractory heart failure despite optimal medical
therapy, requiring more than three admissions in the previous year
with heart failure and are in NYHA class III to IV who have been
started on Sildenafil. Patients were followed up for a mean of
6 months. The following parameters were assessed: freedom from
hospitalization, improvement in NYHA status, reduction in diuretic
use, change of renal parameters, and tolerability of the drug.
Results: 16 patients were treated with Sildenafil. All of the patients
had HFrEF with secondary pulmonary hypertension. 10 were female.
Average age of the patients was 72. 7 had ischemic cardiomyopathy,
7 had valvular cardiomyopathy, and 2 had dilated cardiomyopathy.
All of the patients were in NYHA class IV prior to starting on sil-
danefil. They had, on average, 4 hospitalizations with heart failure in
the previous year. Within 6 months of starting the therapy, 10 patients
improved by 1 NYHA class, and 4 improved by 2 NYHA classes.
There was no significant improvement of renal parameters, but 71%
of patients had down-titration of their diuretic intake due to symptom
improvement. Of note, 2 of the 16 patients were on outpatient mil-
rinone infusions and 1 patient did not tolerate the drug therapy, which
was stopped subsequently.
Conclusion: We observed that the chronic use of Sildenafil in
patients with HFrEF and secondary pulmonary hypertension and
refractory heart failure has improved NYHA status, freedom from re-
hospitalization, and a reduction in diuretic use with good tolerability




39. The Use of Ivabradine in Eligible Heart Failure
Population
Khider W, Boles O
Our Lady of Lourdes Hospital, Drogheda, Co. Louth.
The recently published SHIFT Trial has demonstrated the benefits of
Ivabradine (a novel heart rate lowering agent acting by selectively
inhibiting the If ion current in the SA node) in reducing death and
hospital admissions in symptomatic systolic heart failure population.
Method: We conducted an audit study in our Heart Failure Unit to
identify those patients who could be eligible to receive Ivabradine
therapy based on the SHIFT Trial selection criteria. We defined those
eligible for Ivabradine therapy as any patient who has symptomatic
systolic heart failure NYHA class II–VI, EF B35%, in sinus rhythm
with a heart rate (HR) of 70 bpm or higher, and on maximal tolerable
dose of B-blockers.
Results: The retrospective data of 45 patients attended the Unit were
analysed. The mean age was 66 years. 27 (60%) patients had NYHA
class II–VI. 29 (64.4%) patients had EF B35%. The mean B-blocker
dose was 5.4 mg with 14 (31.1%) patients fully optimized, 27 (60%)
partially optimized and 4 (8.9%) not on B-blockers. There were 38
(84.4%) patients with sinus rhythm and 7 (15.6%) with atrial fibril-
lation. Among the sinus group there were 24 (54%) patients with HR
\60 bpm, 11 (29%) with HR 60–69 bpm and 3 (8.6%) with HR
C70 bpm. Only one patient among the three in the latter group with
HR C70 bpm was eligible to receive Ivabradine as the other two
patients had NHYA class I and EF of 45%, respectively.
Conclusion: The Audit shown that a small proportion of optimised
stable heart failure population are eligible for Ivabradine therapy.
Nevertheless the study recommends the addition of Ivabradine
treatment for eligible patients. We also suggests using 24 h Holter
monitor to measure the mean HR in those with HR 60–69 bpm who
might be eligible for the therapy if the mean HR is 70 bpm or greater.
Re-auditing with the above recommendations is required.
40. Cost Effectiveness of Adding CMR to Evaluation
of Suspected Coronary Ischaemia
Waterhouse DF, Barrett M, Morgan RB, Molloy E, Sheahan R,
McAdam B, Gumbrielle T, Foley D, O’Hanlon R
Cardiac MRI Unit, Blackrock Clinic, Blackrock, Co., Dublin
Introduction: Patient selection for coronary angiography tradition-
ally relies on clinical assessment, treadmill exercise testing (TMET)
and transthoracic echocardiography (TTE). Cardiac magnetic reso-
nance (CMR) is a relatively novel imaging study which provides
excellent non-invasive assessment of myocardial perfusion and is
useful in risk stratification of patients with suspected coronary artery
disease (CAD).
Aims: To estimate the cost and diagnostic implications of using CMR
alone instead of conventional TTE/TMET work-up to guide patient
selection for angiography. Healthcare costs were derived from VHI’s
hospital billing system.
Results: 83 patients (64 male, 19 female) with suspected CAD
underwent CMR. 15.4% had ischaemic features on TMET and 47%
had evidence of territorial ischaemia on TTE. On CMR evaluation,
38.6% of these were found to have definite CAD. Interestingly, 18%
of patients had significant CAD on CMR despite no evidence of
ischaemia on TMET and TTE and would not have undergone angi-
ography based on conventional assessment. In 16 cases (19.3%),
planned angiography based on abnormal TTE/TMET was avoided by
CMR which excluded a diagnosis of CAD. Furthermore, non-
ischaemic causes of cardiac symptoms were discovered on 8.4% of
CMR which were undetected on conventional workup. The use of
CMR as first line investigation in assessment of suspected coronary
ischaemia would have avoided TMET in 31.3%, TTE in 98.7% and
angiography in 25.3%. This would represent a total saving of €18,722,
or €226 per patient.
Conclusions: This study demonstrated that a CMR—only approach is
the most cost-effective diagnostic strategy for evaluation of CAD.
CMR imaging allows accurate selection of patients for invasive
management, avoiding unnecessary procedures. CMR was as useful
as angiography in guiding revascularisation and is superior to TMET/
TTE in detecting ischaemia.
41. B-Type Natriuretic Peptide Association
with Persistent Non-Dipping Nocturnal Blood Pressure
in Patients with Hypertension and Diabetes After
1 year-Early Markers of Diabetic
Voon KJ, Phelan D, Watson CJ, Bhutta U, Elrasheed O, Murphy N,
O’Hanlon R, Ledwidge MT, Ledwidge MT, O’Shea D, McDonald KM
St Vincent’s University Hospital, Elm Park, Dublin
Purpose: Heart failure (HF) is commonly preceded by risk factors like
hypertension (HTN), diabetes (DM) and left ventricular (LV) remod-
eling. Nocturnal non-dipping blood pressure (‘‘Non-dipping’’)
identified by 24-h ambulatory blood pressure monitoring (ABPM) has
been shown to confer additional risk of progressive LV dysfunction and
remodeling. The study aims to define the natural history of non-dipping
in a cohort of patients with HTN and DM over 1 year follow-up.
Methods: This is a prospective analysis with a mean follow-up of
1.2 ± 0.3 years on 107 patients (age 59.7 ± 10.5 years, male 66%,
diabetes 51%, eGFR 114.1 ± 38.5 ml/min/1.73 m2, LVEF 67 ± 8%)
to determine the association between non-dipping status, B-type
natriuretic peptide (BNP) and echocardiographic parameters of LV
dysfunction in patients with HTN and DM.
Results: Persistent non-dipping patients (n = 19) had significantly
higher BNP (median [interquartile] compared to all other patients
(n = 88) at baseline (T0) (26.4 [9.9, 77.4] vs. 9.9 [5.1, 26.8] pg/mL,
p = 0.001) and follow-up (T1) (32.7 [9.4, 70.9] vs. 12.1 [6.1,
29.3] pg/mL, p = 0.03), respectively. This is despite improvement in
daytime blood pressures and left ventricular mass indexes in all
patients with conventional blood pressure management. Elevated
BNP in persistent non-dipping patients was evident in patients with
HTN and DM, but not with HTN alone and was associated with
worsening left atrial volume indexes (LAVi) from T0 to T1
(28.6 ± 9.8, 30.6 ± 10.6 ml/m2).
Conclusion: Plasma BNP elevation is associated with persistent non-
dipping status over 1 year in patients with HTN and DM. It is linked
to increased LAVi, a surrogate for early diastolic dysfunction, and
may reflect an active fibro-inflammatory pathology not resolved by
conventional blood pressure lowering strategies. More work is needed
to understand the causes of persistent non-dipping and elevated BNP
in this patient population.
42. Establishing a Cardiac MRI Programme in Ireland:
1-year Experience
Waterhouse DF, Barrett M, Morgan RB, Molloy E, Sheahan R,
McAdam B, Gumbrielle T, Foley D, O’Hanlon R
MRI Department, Blackrock Clinic, Blackrock, Co. Dublin
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Introduction: Cardiovascular magnetic resonance (CMR) has been
established as the gold standard imaging modality for cardiac dis-
eases. CMR provides exceptional quality images of cardiac and major
vessel anatomy, and allows a robust assessment of a diverse spectrum
of pathology, in addition to functional and physiological parameters.
Objectives: During this initial 1-year experience, we sought to
establish an Irish registry of CMR and to evaluate indications, referral
pattern and impact on patient management.
Methods: This was a single centre registry with consecutive enrol-
ment of patients over a 12-month period.
Results: 521 patients were enrolled. Indications included myocardi-
tis/cardiomyopathies (45.2%), risk stratification in suspected coronary
artery disease/ischemia (24.1%), as well as assessment of viability
(11%). Severe complications occurred in 1.3%, and were all associ-
ated with stress testing. CMR had a significant impact on management
in 60.2% of patients, including importantly, in 32.2% of cases the
final diagnosis based on CMR was different from the diagnosis before
CMR, leading to a complete change in management. In more than
76% of cases, CMR was capable of satisfying all imaging needs so
that no further imaging was required. CMR had therapeutic impli-
cations for 39.6% including both indicating (12.3%) and avoiding
(15.6%) PCI, indication for surgery (7.7%), device indication as a
consequence of CMR (2.1%) and medication change (22.1%).
Conclusions: This initial experience demonstrates the important
clinical impact of CMR on both confirming diagnosis and guiding
appropriate patient management. Within Ireland, the current primary
limitations to routine clinical application of CMR are hardware
availability, clinical acceptance, and physician education. As these
limitations are overcome, the use of CMR will greatly expand.
Indeed, given the diagnostic, and clinical implications, CMR may
become the modality of choice for cardiac imaging.
43. Coronary Calcium is More Effective than Diamond
Forrester for Cardiology Resource Utilisation
at RACPC
McKavanagh P, Donnelly PM, Ball P, Harbinson M, Trinick T,
Lusk L, Doyle P
Ulster Hospital, Dundonald, Belfast
Introduction: Recently revised NICE guidelines for the investigation
of suspected coronary artery disease (CAD) have suggested the use of
modified Diamond Forrester (DF) criteria to rationalise the use of
cardiac imaging resource. It is envisaged that this tool will assist in
the management decisions of patients and reduce unnecessary second
and third line investigations. We compared the use of the Diamond
Forrester likelihood criteria with a coronary artery calcium (CAC)
assessment for the refinement of CAD likelihood.
Methods: This is a preliminary analysis of consecutive patients that
were recruited as part of the CAPP study. The CAPP study is a ran-
domised control trial which will assess the use of cardiac CT against
current standard of care for symptomatic patients that attend rapid
access chest pain clinics (RACPC). The project is supported by the
Southeastern trust research and development office and the Northern
Ireland Cardiac Research Network. Ethical approval was obtained from
the Northern Ireland Research Ethics Committee. Prospective demo-
graphic information such as age, gender, type of chest pain and
traditional risk factors was collected at RACPC and entered into a
Diamond Forrester likelihood table. Patients with likelihood \10%
were considered low risk and did not require further investigation,
11–89% moderate risk further cardiac non-invasive cardiac imaging
required,[90% high risk and cardiac catheterisation required. A non-
contrast enhanced CAC was performed on a 64 multidetector CT
platform. CAC scan parameters were tube voltage 120 kV, tube current
165 mA, and 3 mm reconstruction increment. CAC was assessed using
a semi-automated analysis package to determine the total Agatston
score. CAC score\10 was considered low risk no further investigation
required, 11–399 moderate risk non-invasive cardiac imaging required,
[400 high risk, cardiac catheterisation required.
Results: 78 patients were assessed. 38 Female, 40 male. Mean age 59
(SD 9.61). The mean DF likelihood of disease was 59 (SD 29). The mean
CAC was 186. The median female CAC was 0 (range 0–1,738) in the
median male CAC was 20 (range 0–2,885). 73% of patients would have
required further non-invasive imaging tests and 13% would have required
an invasive angiogram based on DF criteria. When CAC was used as
gatekeeper for further investigation, 28% would have required non-
invasive cardiac imaging and 13% would have required an invasive
angiogram. 20% of those considered to require invasive angiography by
DF criteria would not have received it and 14% of those considered for
non-invasive testing would have been considered for invasive angiog-
raphy when CAC criteria was applied.
Conclusions: The prediction of coronary artery disease burden and
cardiovascular risk remains an imperfect science. Total CAC scores
are strongly associated with total atherosclerotic plaque burden, with
correlation coefficients[0.90 [1]. This pilot study suggests that CAC
may prove more effective at rationalisation of healthcare resource
than DF criteria for patients with suspected CAD.
Reference
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44. Increase in Isovolumic Acceleration (IVA)
of the Right Ventricular (RV) Free Wall but No
Difference in NT-proBNP Between Endurance Athletes
with Athlete’s Heart and Healthy Untrained Controls
at Rest
McLoughlin B, Flynn I, Clarke J, King G
Eagle Lodge Cardiology, Limerick
Background: It is unclear if the exercise associated increase in RV
end diastolic wall stress in healthy athletes represents a clinically
significant risk for RV insult or is apart of the physiological response
to endurance exercise.
Methods: 18 male elite athletes were compared to a similarly aged
group of 17 male controls. IVA was measured at the lateral corner of
the tricuspid annulus. RV diameter, RV wall thickness, and pulmonary
pressure (PAP) were also measured. Independent t tests were used to
compare RV diameter, RV thickness, and PA pressures. A non-para-
metric Mann–Whitney U test was used to compare IVA between the
two groups. A p value of \0.05 was considered significant. NT-
proBNP was measured by an electrochemiluminescence assay.
Results: In the Elite athlete, the mean RV diameter was 34.0 (SD 6.77)
compared to 22.5 (SD 6.92) in the control group (p\ 0.0001). The mean
RV wall thickness for athletes was 0.422 (SD 0.10) and for controls was
0.359 (SD 0.11) (p\ 0.063). The mean resting PAP was 23.29 mmHg
(SD 6.04) in the Athletes and in the control group 21.12 mmHg (SD 4.4).
The mean IVA in the athletes was 2.02 M/s (SD 0.60) compared to
1.48 M/s (SD 0.30) in the controls (p = 0.002). LV myocardial com-
pliance improved. There was no difference in NT-proBNP values
between endurance athletes and untrained control subjects (p = 0.56).
Conclusions: This study showed a significant increase in IVA of the RV
in the athletes despite normal levels in NT-proBNP. The increase in IVA
therefore is not a compensatory response to a cardiac insult but represents
a part of the physiological response to endurance exercise.
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45. Atrial Septal Pouches: Can they be Identified
on Transoesophageal Echocardiogram?
O’Flynn AM, Moore DP
The Adelaide and Meath Hospital Incorporating the National
Children’s Hospital (AMNCH), Tallaght, Dublin
Purpose: The presence of atrial pouches in pathological specimens
has recently been described. This has generated theories regarding the
process of fusion of the septum primum and secundum. It has been
postulated that a left atrial pouch may be a potential source of sys-
temic embolism. We carried out a retrospective review of 100
transoesophageal echocardiograms to assess if the presence of atrial
pouches as recently described could be established.
Methods: All patients who undergo transoesophageal echocardiog-
raphy at our centre to assess for potential cardiac source of embolism
receive an agitated saline contrast injection as protocol. This increases
the detection rate for patent foramen ovale (PFO). As part of this
protocol a detailed examination of the interatrial septum is also carried
out. We selected 100 consecutive transoesophageal echocardiograms
with the main indication being assessment for cardiac source of
embolism. We reviewed the studies in detail paying particular atten-
tion to the interatrial septum.
Results: Left atrial pouches were identified in 27 of the 100 cases
reviewed. A PFO was identified in 28 of the cases and a right atrial
pouch was identified in 13 cases. It was deemed that 31 of the cases
had complete fusion of the septum primum and secundum.
Conclusions: Based on our observations atrial pouches are readily
identifiable on transoesophageal echocardiogram. The frequency of
left atrial pouches was lower while that of right atrial pouches was
higher than recently described. However this was a retrospective
review. Atrial septal pouches are an interesting anatomical entity and
future prospective studies should focus on their detection, and attempt
to draw conclusions regarding their potential as a source of embolism.
46. Cardiac CT in an Emergency Department Chest
Pain Evaluation Unit in Ireland
1Kearns G, 1Erwin J, 1Keane D, 1McCreery C, 1McDonald K,
1Quigley P, 1Quinn M, 2Dodd, J
1Department of Cardiology, St. Vincent’s University Hospital, Elm
Park, Dublin, 2Department of Radiology, St. Vincent’s University
Hospital, Elm Park, Dublin
Purpose: To evaluate the outcomes of patients with low or inter-
mediate clinical likelihood of acute coronary syndrome (ACS) who
underwent a cardiac CT attending an emergency department ‘Chest
Pain Evaluation Unit’ (CPEU) in Ireland.
Materials and Methods: From August 2008 through December
2009, 1,183 consecutive CPEU patients attended the emergency
department at St. Vincent’s University Hospital and were assessed by
the Cardiology Advanced Nurse Practitioner (ANP). One-hundred
and four patients with low-to-intermediate pre-test probability were
deemed suitable for cardiac CT. Those patients with a negative car-
diac CT were discharged and those patients with a positive cardiac CT
(at least one obstructive coronary lesion) underwent invasive coronary
angiography. Follow up phone calls were made at 1-year post cardiac
CT to the patient’s general practitioners (GPs) to determine the
occurrence of major adverse coronary events (MACE).
Results: Thirty-three patients underwent cardiac CT while in the
CPEU and 71 underwent cardiac CT as an outpatient. The mean time
interval between admission to CPEU and cardiac CT was 15.4 h
(±18.7) for inpatient scans and 28.8 days (±21.2) for outpatient
scans. Of the 104 patients, 62 had normal coronary arteries on cardiac
CT and 28 had non-obstructive coronary artery disease. Four patients
did not attend for CT. None of these patients reported MACE at
1-year. Ten patients had at least one obstructive coronary lesion
diagnosed on CT and subsequently underwent invasive coronary
angiography. Six showed confirmed obstructive coronary disease; two
of these were revascularized. Thus, cardiac CT had a sensitivity of
100%, specificity of 95.2%, positive predictive value of 60% and
negative predictive value of 100% for obstructive coronary artery
disease.
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47. Potent Long-term Cardioprotective Effects of Single
Low Dose Insulin-like Growth Factor-1 (LD-IGF-1)
Treatment Post Myocardial Infarction
O’Sullivan J F, Leblond AL, Kelly G, Kumar A HS, Metharom P,
Bu¨neker CK, Alizadeh-Vikali N, Hristova I, Hynes BG, O’Connor R,
Caplice NM
Centre for Research in Vascular Biology, Biosciences Institute, UCC,
Cork
Background: Insulin-like growth factor-1 (IGF-1) is recognized as an
important regulator of cardiac structure and cardiomyocyte homeo-
stasis. The pro-survival and anti-apoptotic effects of IGF-1 have been
investigated in vitro and in rodent models of myocardial infarction
(MI). However, the clinical application of IGF-1 has been hampered
by dose dependent side effects both acutely and during chronic
administration. We hypothesized that single, low dose IGF-1 (LD-
IGF-1) administered locally and early in the reperfusion phase after
acute MI in a large animal model would avoid significant side effects
but would have pro-survival effects that would manifest in long-term
structural and functional improvement post MI treatment.
Methods and Results: Forty-four female Landrace pigs underwent
intracoronary administration of LD-IGF-1 or saline 2 h into the
reperfusion phase of acute LAD occlusion MI. In the area of infarc-
tion, IGF-1 receptor and signaling responses were activated at 30 min,
and cardiomyocyte cell death was attenuated at 24 h, post-LD-IGF-1,
but not saline, treatment. Hemodynamic and structural studies using
PV loop, CT and TTC analysis 2 months after MI confirmed marked
reduction in infarct size, attenuation of wall thinning and augmenta-
tion of wall motion in the LD-IGF1 but not saline treated animals.
These regional structural benefits were associated with global




Conclusions: One-time LD-IGF-1 effects potent acute myocardial
salvage in a preclinical model of LAD occlusive MI extending to
long-term benefits in myocardial infarct size, wall structure and
function, underscoring its potential as an adjunctive therapeutic agent.
48. Waveform Optimisation for Internal Cardioversion
of Atrial Fibrillation
1Kodoth V, 2Castro NC, 1Glover BM, 3Anderson JM, 3Escalona OJ,
1Lau E, 1Manoharan G
1The Heart Centre, Royal Victoria Hospital, Belfast, NI, 2Department
of Electronics, Universidad Simon Bolivar, Caracas, Venezuela,
3Northern Ireland Bio-Engineering Centre, University of Ulster,
Jordonstown, NI
Introduction: A novel atrial defibrillator was developed at the Royal
Victoria Hospital in collaboration with Northern Ireland Bio-Engi-
neering Centre (NIBEC), University of Ulster. This device is powered
by an external pulse of radiofrequency (RF) energy and designed to
cardiovert using low tilt monophasic (LTMW) and low tilt biphasic
waveform (LTBW). This study compared the safety and efficacy of
LTMW with LTBW for transvenous cardioversion of atrial fibrillation
(AF).
Methods: Patients with persistent AF with previous history of failed
external cardioversion were randomised to LTMW or LTBW. INR
was maintained in between 2 and 3 for 4 weeks prior cardioversion.
St Jude’s defibrillating catheter was positioned in the distal coronary
sinus and right atrium and connected to the defibrillator via a junction
box. After dummy testing patient was cardioverted in a stepwise
progression from 50 to 300 V. Shock success was defined as return of
sinus rhythm for C30 s. If cardioversion was unsuccessful at peak
voltage patient was crossed over to the other arm and cardioverted at
peak voltage.
Results: Thirty patients (50%) were equally randomised to LTBW
and LTMW. Seven out of 15 (46%) cardioverted to sinus rhythm with
LTBW and 1/15 (6%) with LTMW (p \ 0.035). Including crossover
patient’s 14 patients (46%) converted to sinus rhythm. After cross
over four patients were cardioverted with LTBW and two with
LTMW. Mean voltage, current, energy and intracardiac impedance
used for cardioversion was 270.53 ± 35.96 V, 3.68 ± 0.80 A,
9.12 ± 3.73 J and 70.82 ± 13.46 Ohm. For patients who were suc-
cessfully cardioverted mean voltage, current, energy and intracardiac
impedance were 268.28 ± 42.41 V, 3.52 ± 0.63 A, 8.51 ± 3.16 J
and 73.92 ± 12.01 Ohms. There were no major adverse complica-
tions during the procedure. Cardiac markers measured post
cardioversion was unremarkable.
Conclusion: LTBW was more efficacious for low energy transvenous
cardioversion of AF. Significant proportion of patients were suc-
cessfully cardioverted to sinus rhythm with low energy.
Radiofrequency powered defibrillator can be safely used for trans-
venous cardioversion of AF.
49. LRG: a Novel Biomarker of Ventricular
Dysfunction and Heart Failure
*Watson C J, *Ledwidge MT, *Phelan D, *Collier P, *Byrne JC,
*Dunn MJ, *§McDonald KM, *§Baugh JA
*School of Medicine and Medical Science, St Vincent’s University
Hospital and The Conway Institute of Biomolecular and Biomedical
Research, University College Dublin, Heart Failure Unit,
St Vincent’s University Hospital Healthcare Group, Elm Park,
Dublin, §Denotes equal author contributions
Purpose: Heart failure (HF) preventative strategies urgently require
better biomarkers for optimal risk stratification. The current gold
standard B-type natriuretic peptide (BNP) correlates with increased
risk of cardiovascular events and is reflective of an active pathological
process. However, BNP possesses numerous limitations, including
wide biological variability. A search for biomarkers with improved
performance characteristics requires application of more innovative
methodologies.
Methods: To maximise cardiac specificity for biomarker identifica-
tion, we obtained serum from the coronary sinus of asymptomatic
patients with hypertension. Serum was pooled into two groups
according to BNP levels. Using a novel proteomic methodology, we
isolated differentially expressed proteins within the coronary sinus
serum proteome and identified them by mass spectrometry. An
extensive validation process at gene and protein level were carried out
in various cohorts of patients across a wide spectrum of cardiac
disease, extending from asymptomatic left ventricular diastolic dys-
function through to systolic HF.
Results: Leucine-rich a2-glycoprotein (LRG), a protein whose pre-
cise function is still unclear, was identified as being consistently over-
expressed in high BNP serum. LRG levels correlated significantly
with BNP (P \ 0.05) yet were able to identify HF independent of
BNP. Furthermore, LRG expression was detected in myocardial tissue
and correlated with expression of fibrotic genes (P \ 0.001). Impor-
tantly, increasing serum levels of LRG over time was associated with
progressive left ventricular diastology.
Conclusion: We have identified LRG as a novel serum biomarker that
can accurately identify patients with HF. Multivariable modelling
confirmed that LRG is a stronger identifier of HF than BNP and this is
independent of age, sex, renal function, medications, and BNP. Fur-
thermore, unlike BNP, LRG was able to predict changes in left
ventricular diastology over time highlighting a potential role for
identification of sub-clinical disease progression in pre-HF syndromes.
50. Exercise Training Improves Activity
and Psychosocial Wellbeing in Adolescents
with Congenital Heart Disease (CHD)
1Morrison ML, 1Sands AJ, 1,2McCusker CG, 2McKeown PP,
1McMahon M, 1Gordon J, 1Craig BG, 1Casey FA
1Department of Paediatric Cardiology, The Royal Belfast Hospital for
Sick Children, Belfast, 2The Queen’s University of Belfast, Belfast
Ability to exercise is an important quality of life measure and
indicator of physical health. Recently, exercise training has emerged
as a method of improving activity and psychological health in some
patient groups. Many patients with CHD are now adolescents; this
time of personal development may be an ideal opportunity to
introduce positive lifestyle changes. We aimed to ascertain if
motivational techniques and a structured exercise program could
increase activity and improve wellbeing. Patients aged 12–20 years
were identified using the Northern Ireland regional database
(HeartSuite). Participants completed standard psychological ques-
tionnaires and underwent evaluation of exercise ability (formal
exercise stress testing and measurement of free-living activity using
an ActiGraph accelerometer). Following randomisation the inter-
vention group attended an activity day where they were given a
personal exercise programme. The control group received their usual
level of care. Patients were followed up at 6 months for reassess-
ment and results obtained were analysed using parametric methods.
One hundred and forty-three patients (mean age 15.6 years) con-
sented to participate, 86 were male (60%) and 105 had major CHD
(73%). Psychological health appeared well preserved at baseline
with few differences between study groups. On formal exercise
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testing, complex patients performed worse at peak exercise. How-
ever, patients with major CHD had significantly higher activity
counts. 101 (71%) attended for reassessment. There was a signifi-
cant increase in duration of exercise test [Pillai’s Trace 5.34 (p
0.023)] and average activity counts per minute [Pillai’s Trace 46.55
(p \ 0.001)] for the intervention group at reassessment. The inter-
vention group also had trends toward improved mood and self
esteem. Exercise training significantly improves peak exercise
capacity and free-living activity in this group. Increased activity
also appears to have a positive effect on self-esteem and mood
parameters. Future interventions targeted around this area may
considerably improve outcomes for this population.
Session 8: Revascularisation
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51. Duration of Balloon Inflation for Optimal Stent
Deployment: 5 Seconds is Not Enough
Mylotte D, Hovasse T, Garot P, Salvatella N, Morice MC, Chevalier
B, Pichard A, Lefe`vre T
Institute Cardiovasculaire, Paris Sud
Aim: To assess the effect of the duration of stent inflation on stent
expansion using digital stent enhancement (DSE).
Background: Optimal stent expansion and apposition to the vessel
wall are of critical importance to optimize the results of percutaneous
coronary intervention (PCI). However, it is not known if stent infla-
tion duration impacts on stent expansion.
Methods: We performed a prospective cohort study in patients
undergoing PCI. Quantitative coronary angiography and DSE data
were analysed. DSE was performed at 5, 15 and 25 s during stent
implantation, after target balloon inflation pressure was achieved.
Results: 104 consecutive patients (150 lesions) were enrolled. The
mean age was 66.9 ± 11.1 years. Complex lesions (ACC/AHA B2/
C) occurred in 26.9%. Stents used: Cypher Select (54.1%), Xience V
(30.6%), and Taxus Liberte´ (15.3%). The minimal stent diameter
increased significantly with the duration of stent inflation:
2.60 ± 0.51, 2.76 ± 0.51, 2.82 ± 0.52 mm at 5, 15 and 25 s
(p = 0.001). Similarly, maximal stent diameter increased with the
duration of stent inflation: 3.21 ± 0.51, 3.32 ± 0.52, and
3.36 ± 0.54 mm (p = 0.05). The average stent diameter also
increased with longer stent inflation (p = 0.021). Using MUSIC cri-
teria 24.0, 53.3, and 68.0% of stents were appropriately expanded at
5, 15 and 25 s (p \ 0.0001).
Conclusions: The duration of stent balloon inflation has a significant
impact on stent expansion. Stent deployment for [25 s is
recommended.
52. Syntax Scoring in Multivessel Coronary Artery
Disease: a Multidisciplinary Approach is Best
Hodkinson EC, Noad RL, Spence MS, Johnston PWJ
Cardiology Department, Royal Victoria Hospital, Belfast Trust,
Belfast
Introduction: When determining the best revascularization strategy
for a patient with left main +/- multivessel coronary disease, the
European Society of Cardiology recommends a multidisciplinary
‘Heart Team’ approach [1]. A key part of this decision-making is the
use of scoring systems to help standardise risk stratification. The
SYNTAX Score (Synergy between PCI with TAXUS drug-eluting
stents and Cardiac surgery) quantifies lesion complexity based on its
angiographic appearance and places the patient in a ‘risk tertile’
(low = 0–22, Intermediate = 23–32, high = C33). The 3-year
SYNTAX results showed no significant difference in MACCE rates
between PCI and CABG in the lowest tertile. However, in the
Intermediate and high risk groups MACCE were higher in the PCI
group [2]. The SYNTAX Trialists recommend that scoring is best
done by a panel of three, yet within the CardialysisTM core scoring lab
there is an inter-observer variability of ±9.1 [3]. This study assesses
our Heart Team’s Syntax scoring and the potential impact on revas-
cularisation strategy chosen.
Methods: Five recent coronary angiograms were selected, and all
cardiologists and cardiac surgeons in our department were invited to
score the cases independently. The cases were also scored by a
SYNTAX score Proctor.
Results: 18 doctors responded (six cardiologists, two surgeons, six
cardiac registrars and four cardiothoracic registrars). In 35% of cases
the individual scores differed in tertile allocation from the Proctor.
This may have altered the revascularistion strategy chosen. In contrast
the mean departmental scores were in agreement with the Proctor.
Those cases in the lowest tertile produced the widest variations
between scorers. Overall, our department’s inter-observer scoring
variability was lower than that of the Cardialysis corelab, at ±5.1.
Conclusions: If using SYNTAX score to assist Heart Team revas-
cularisation decisions, we recommend that the scoring should be
performed by at least two members of the Heart Team.
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53. Total but not Partial Discontinuation of Antiplatelet
Therapy in ACS Presenters Predicts Poor Clinical
Outcome
O’Connor S, Collet JP, Hattab M, Tanguy ML, Silvain J,
Barthelemy O, Bellemain-Appaix A, Beygui1 F, Montalescot G
Institut de Cardiologie, INSERM CMR937, Pitie´-Salpeˆtrie`re Hospital
(AP-HP) 75013 Paris, France Universite´ Pierre et Marie Curie, Paris,
France
Background: Cessation of Antiplatelet Therapy (APT) is detrimental,
especially after stent placement. The effect of partial cessation (one
remaining APT drug) of dual antiplatelet therapy (DAPT) versus
complete cessation (cessation of all APT drugs) of APT requires
further clarification with respect to its prevalence in acute coronary




Aim: To evaluate the prevalence of complete versus partial inter-
ruption of APT in ACS presenters and to evaluate early recurrent
events after admission for ACS with respect to prior pattern of
chronic APT use. The primary endpoint was a composite of death,
myocardial infarction and stent thrombosis occurring during the first
month after admission for ACS. Safety outcome was a composite of
TIMI major and minor bleeds.
Methods and Results: Of 3,514 ACS presenters recruited in the
e-PARIS web-registry between 1999 and 2009, 2,528 were prior users
of APT and n = 852 were APT-naı¨ve patients. Prior users were at
higher risk than naı¨ve patients but presented less frequently with
STEMI (42.26 vs. 23.12%, p = \0.0001). Among prior users, 133
(3.8%) patients interrupted APT of which 115 were complete (96 single
APT and 19 DAPT) and 18 partial interruptions. The median time from
interruption to ACS was 53.4 and 21.3 days for partial and complete
interruption, respectively. The primary endpoint occurred in 363
patients including 268 deaths, 327 MIs and 39 stent thrombosis.
Complete interruption was found to be an independent correlate of the
primary composite endpoint (OR 1.712, 95% CI 1.04–2.81, p = 0.034)
along with STEMI presentation, prior PCI, diabetes, age and impaired
renal function. Independent correlates of bleeding events (TIMI major
and minor) were prior APT treatment (OR 2.06, 95% CI 1.14–3.75,
p = 0.016) along with female gender, STEMI presentation and age.
Conclusion: The pattern of chronic APT use remains an important
marker of CV risk. Interruption of the last or only APT drug appears
as a major risk factor for the occurrence of a major thrombotic cor-
onary event.
54. Impact of Renal Insufficiency on Prescription
of Discharge Medication and 1 year Outcomes After
Percutaneous Coronary Intervention
#Margey R, Selzer F, *Quiroz R, Jneid H, Marroquin OC,
Mulukutla SR, §Laskey WK, *Jacobs AK,*Maree AO
#Massachusetts General Hospital, Harvard Medical School, Boston,
MA, *Boston University School of Medicine, Boston Medical Center,
Boston, MA, Graduate School of Public Health, University of
Pittsburgh, Pittsburgh, PA, Michael E. DeBakey VA Medical Center
and Baylor College of Medicine, Houston, TX, §University of New
Mexico School of Medicine, NM
Background: Degrees of renal insufficiency strongly predict death
and cardiovascular events after percutaneous coronary intervention
(PCI). However, little is known about how varying degrees of renal
insufficiency impact the prescription of cardiovascular medication in
PCI patients.
Aims: To determine if renal insufficiency influences prescription of
recommended Class 1 medication at the time of hospital discharge.
To establish if there is a relationship between degrees of renal
insufficiency, failure to prescribe antiplatelet pharmacotherapy and
outcome in patients who have undergone PCI.
Methods: This was a prospective, multi-center, cohort study of
consecutive patients undergoing PCI during three NHLBI Dynamic
Registry recruitment waves (2001–2006). Rates of prescription of
statin, aspirin, thienopyridine, beta blocker, ACE inhibitor and
Coumadin for discharged patients were correlated with degrees of
renal insufficiency. Estimated glomerular filtration rate (eGFR) was
calculated using the MDRD equation (required serum creatinine, age,
race, gender). Major adverse cardiovascular events (MACE) consisted
of death, myocardial infarction and repeat revascularization. Statis-
tical analysis comprised Kruskal–Wallis test, Chi-square and
Cochran-Mantel–Haenszel test for trend. One year event rates were
calculated by Kaplan–Meier method.
Results: Patients with renal insufficiency who underwent PCI were
less likely to be prescribed cardiovascular medication on discharge.
The percentage of patients discharged on statins, antiplatelet therapy,
beta blockers and ACE inhibitors was inversely proportional to the
degree of renal insufficiency. Failure to prescribe antiplatelet therapy
at discharge was strongly associated with increased MACE at 1 year
(MACE rate of 43% off Thienopyridine vs. 23% on Thienopyridine,
p \ 0.001).
Conclusions: (1) Patients with even mild or moderate degrees of
renal insufficiency are less likely to receive optimal discharge phar-
macotherapy after PCI despite higher cardiovascular risk. (2) An
incremental decline in the prescription rate of all guideline recom-
mended medications including those with a Class I indication is
evident, not only those with relative contraindication in patients with
renal impairment. (3) Failure to prescribe a thienopyridine at dis-
charge was associated with significantly increased MACE at 1 year.























Statin (%) 73.6 76.4 81.9 81.6 \0.001 \0.001
Aspirin (%) 93.7 95.5 96.7 96.9 \0.001 \0.001
Clopidogrel (%) 93.4 93.9 95.6 96.4 \0.001 \0.001
Beta blocker (%) 80.8 76.0 80.5 81.5 0.003 0.03
ACE Inhibitor %) 45.9 52.3 52.9 51.5 0.02 0.10
Coumadin (%) 11.7 10.0 7.4 6.3 \0.001 \0.001
55. In Primary Percutaneous Coronary Intervention
Mortality is Low and Largely Predictable
Dooley M, Belfast Trust pPCI Service Group
Belfast Trust, Belfast
Introduction: The National Infarct Angioplasty Project (NIAP)
reported a low in-hospital mortality of 4.4% for primary percutaneous
intervention (pPCI) for ST elevation myocardial infarction (STEMI).
A 24/7 pPCI service was commenced in Belfast in December 2009.
We have audited our results against this standard and looked for
recognised predictors of adverse outcome.
Results: In the 13 month period from February 2010 to February
2011 a total of 236 patients activated the pPCI pathway. Of the 236
patients, 24 (10%) were non acute coronary syndrome and 9 patients
had a non-STEMI. The remaining 203 patients had STEMI and 198
proceeded to pPCI. 5 STEMI patients did not have pPCI (died before
lab, age 99, distal disease, normal coronaries, coronary artery dis-
section). Analysis was performed on the 203 patients with STEMI.
There were ten in hospital deaths (4.9%) (7 male, mean age 67.3;
range 37–89). One patient died from cardiogenic shock before
reaching the catheterisation lab, three died in the lab, three within
48 h and one each on days 7, 28 and 44. Four of the ten patients had
cardiac arrest on admission and eight had cardiogenic shock. Intra-
aortic balloon pump was used in seven cases and temporary pacing in
one case. Of the nine patients undergoing angiography all had left
main stem or severe triple vessel disease, Angioplasty was attempted
in eight cases and angiographic success achieved in four cases (two
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with TIMI 3 flow). Of the six patients who survived the procedure one
died suddenly and the others from pump failure.
Conclusion: In hospital mortality for all comers in a pPCI programme
is low and deaths are largely predictable.
56. Single Centre Experience of Contemporary
Rotablation Atherectomy
Pal N, Spence M, Manoharan G, Dalzell G, Wilson C, Hanratty C,
Walsh S, Riddell J, Johnston P
Royal Victoria Hospital, Belfast
Introduction: Early experience with rotational atherectomy, using
high burr-to-artery ratios, resulted in a high complication rate. Con-
temporary practice employs a strategy of lesion modification, using
smaller burrs, to facilitate stent implantation. We report a single
center experience.
Results: A total of 156 rotablations were performed over a 35 month
period from May 2008. The mean age was 73.2 years (range 43–95)
(73% male). 27 patients were ‘‘surgical turn downs’’ and 6 were part
of a transcatheter valve programme. Most patients had one vessel
treated (71%), the remainder were double vessel procedures. Vessels
treated—LAD (49%), RCA (26%), left circumflex (14%) and left
main stem (11%). 46% of lesions involved a bifurcation. Most pro-
cedures (61%) were performed by 2 consultants. Mean procedure
time was 123.6 min and mean screening time 30.2 min. IVUS was
used in 59 cases, temporary pacing in 39 cases and IABP support in
10 cases. A Guideliner was needed in 15 cases. A single burr strategy
was most common (58%), two burrs were used in 38% cases and three
burrs in 4%. The most common burr size was 1.5 mm (55%), fol-
lowed by 1.25 mm (24%), 1.75 mm (18%), 2 mm (2%) and 2.5 mm
(1%). Stents were successfully deployed in all but one case, 96% were
drug eluting. A one stent strategy was most common (44%) followed
by two stents (36%), three stents (15%), four stents (3%) and six
stents (2%). Mean stent length was 27.3 mm (95% CI 25.5–29.1),
mean diameter was 3.3 mm. Angiographic success was 100%. Cor-
onary perforation occurred in six cases (3.8%) requiring covered stent
in five cases (3.2%). No patient required pericardiocentesis or
emergency CABG. ST elevation myocardial infarction occurred in
three cases. One patient died from a retroperitoneal bleed 24 h post
procedure. Contemporary rotablation can be performed in complex
patients with low procedural risk.
Poster Presentation
57. Re-Fibrillating the Atrium with Low Energy,
Synchronized Shocks after DFT Testing
Cronin EM, Baranowski BJ, Chung R, Wazni O, Kanj M, Saliba W,
Callahan T, Borek P, Martin DO
Cleveland Clinic, Cleveland, OH USA
Background: Many patients undergoing defibrillator (ICD) implan-
tation are in atrial fibrillation (AF) at the time of the procedure. If
defibrillation threshold (DFT) testing is performed, a patient in AF
may convert to sinus rhythm (SR). If anticoagulation is stopped prior
to ICD implantation, the patient may be at increased risk for a
thromboembolic event if left in SR. It is standard practice in our lab to
re-induce AF if a patient converts to SR following DFT testing and is
not therapeutically anticoagulated.
Objective: The purpose of this study is to describe our experience
with patients in AF who undergo ICD implantation and DFT testing.
Methods and Results: We reviewed 501 consecutive patients who
presented to our lab in AF and underwent DFT testing between 1/1/
2002 and 1/1/2010. DFT testing converted 191 patients (38%) to SR.
Patients were more likely to convert when more shocks were deliv-
ered (1.5 vs. 1.9 shocks, p = 0.001) and when their pattern of AF was
paroxysmal versus persistent (p = 0.03). The mean maximum
delivered shock of those wh converted was higher than those who did
not convert (17 vs. 15 J, p = 0.01). Of the 191 patients who con-
verted, we attempted to re-induce AF in 150 (78%). The most
commonly used method to re-induce AF was rapid atrial pacing,
either through the implanted DDD device (n = 137) or via an EP
catheter (n = 23). This mechanism was successful at reinducing AF
in 137 if 140 patients (98%). In ten patients who did not have an atrial
lead a low energy shock (1 or 2 J) synchronized to the QRS complex
was used. This method was successful in nine of the ten patients. The
rate of success did not differ significantly between the two re-
induction approaches (p = 0.28). The single patient who failed to
have AF re-induced with a synchronized low energy shock could also
not be re-induced with burst pacing.
Conclusion: A low energy shock synchronized to the QRS complex is
a feasible mechanism for the re-induction of AF and should be con-
sidered when attempting to re-induce AF after DFT testing, especially
in patients who do not have an atrial lead.
58. A Comparison of Complication Rates Between
Active and Passive Pacemaker Leads
Matiullah S, Canniffe C, Boyle M, Aziz W, Phelan D, O’Sullivan B,
Daly K, Crowley J, Sharif F, MacNeill B, Nash P
Galway University Hospital, Galway
Previous studies report a similar rate of complications in active and
passive atrial leads, however they do report an increased rate of lead
dislodgement with passive atrial leads. There is little data comparing
active and passive ventricular leads. We reviewed patients who
underwent permanent pacemaker implantation between 1 January and
31 December 2010 to determine if there was a significant difference
in complication rate between active and passive atrial and ventricular
leads.
Methods: Patients were identified through the cardiac technician
database. A systematic review of implantation record, patient dis-
charge summaries and any recorded complications were noted.
Patient charts were reviewed if data from these records was insuffi-
cient for study purposes.
Results: 208 patients were identified. 55.2% of the population were
male. Mean Age was 75.9 years (range 34–98 years) 67.7% of
implanted devices were single chamber devices, with dual chamber
devices accounting for 32.2%. In single chamber devices the number
of active and passive leads were 96 (68.5%) and 44 (31.4%),
respectively. Of the dual chamber devices, 88% of ventricular leads
were active fixation leads, whilst 76.1% of atrial leads were active
fixation. Lead failure was the commonest complication being reported
in 2.8% of all cases. Amongst ventricular leads, there were six cases
of lead failure. These were all reported in active leads, amounting to a
3.8% lead failure rate in ventricular active leads versus 0% rate of
lead failure in ventricular passive leads. 83.3% of lead failures were
found to be secondary to lead movement and threshold changes.
There were four reported cases of lead failure amongst atrial leads,
amounting to a 5.9% rate of lead failure. 50% of these were in the
active atrial leads versu 50% in passive leads. Again, the commonest
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reason for lead failure was either movement and threshold change. All
these cases required a repositioning procedure. There was no signif-
icant difference between the two groups in terms of infection rates,
pocket complications or pneumothorax occurence.
Conclusion: We found no significant differences between active and
passive atrial leads in terms of lead failure and other complications.
There was a higher rate of ventricular lead failure amongst active
leads, with no reports of lead failure amongst passive leads.
59. Varying Prevalences of Chronotropic Incompetence
from Different Disease Definitions
Groarke J, Lim RY, Owens P, Maree AO
Department of Cardiology, Waterford Regional Hospital, Waterford
Introduction: Chronotropic incompetence (CI) is often overlooked in
clinical practice however is common, and has symptomatic and
prognostic implications for patients. The aim of this study was to
investigate the prevalence of CI among patients undergoing Bruce
protocol exercise stress tests (ESTs).
Methods: Data on consecutive patients (n = 295) who underwent
ESTs between 5/11/10 and 26/1/11 were analysed, retrospectively.
Data were analysed using following definitions of CI: failure to
achieve: (1) [80% of maximum age predicted HR (MPHR); (2)
[85% of MPHR; (3) a HR \120 bpm; (4) or a chronotropic index
\0.8 at maximum exercise. MPHR at peak exercise was calculated
using the Astrand’s formula: (220-age) bpm. Chronotropic index was
defined as a ratio of percentage of HR reserve used to percentage of
metabolic reserve used. Percentage of HR reserve is calculated as
(maximum HR achieved-resting HR)/(MPHR - Resting HR) 9 100.
As all patients underwent symptom-limited testing the proportion of
metabolic reserve used has a value of 1, and thus chronotropic index
can be simplified as the fraction of HR reserve used at peak exercise.
All AV nodal blocking medications were interrupted for 72 h prior to
EST in all patients. Correlation with available echocardiography data
was performed. Students t test and Fischer’s exact test were used for
analyses.
Results: 295 patients were included in analyses outlined in Table 1:
25 (9%) patients satisfied all 4 definitions used, 12 (4%) satisfied 3 of
4 definitions and 16 (5%) satisfied 2 of 4 definitions.
Conclusions: The prevalence of CI varies from 8 to 27% within the
same patient cohort depending on the definition used. Patients with CI
were significantly older, had lower resting HRs and achieved fewer
peak metabolic equivalents during exercise. Symptoms were more
likely to limit patients with CI during exercise but duration of exercise
tolerated did not differ significantly. Consensus on a definition that
identifies clinically relevant CI is needed.
60. Implantable Cardioverter Defibrillator Therapy
in a Mixed Adult Congenital Heart Disease Population
Joyce E, O’Brien C, Buckley U, Keaney J, Doran E, Savage R,
Walsh K
Mater Misericordiae Hospital, Eccles St, Dublin
Introduction: Sudden death accounts for a lower fraction of mortality
in adult congenital heart disease (ACHD) than acquired heart disease.
Meanwhile significant variability in sudden death risk exists between
different anatomic diagnoses. Therefore current accepted guidelines
regarding implantable cardioverter defibrillator (ICD) implantation in
the acquired heart disease population are difficult to extrapolate to this
population. The aim of the study is to review ICD usage including
patient characteristics, frequency of appropriate therapies and adverse
events in our mixed ACHD national referral centre cohort.
Methods: Patients with ICDs were selected from chart reviews of
current attendees at the ACHD national clinic. Baseline clinical
characteristics including age, diagnosis, prior surgeries and/or palli-

















n (%) 37 (13%) 258 (87%) 49 (17%) 246 (83%) 22 (8%) 273 (82%) 79 (27%) 216 (73%)
Age, mean (SD) 63 (11) 56 (14) 0.002 61 (12) 56 (14) 0.02 64 (9) 56 (14) \0.001 61 (13) 55 (14) 0.002
Males (%) 25 (68%) 161 (62%) 65% 63% 15 (68%) 171 (63%) 51 (65%) 135 (63%)
Resting HR, mean (SD) 67 (14) 81 (15) \0.001 72 (14) 81 (15) \0.001 67 (14) 81 (15) \0.001 77 (14) 81 (16) 0.04
Exercise Capacity
METS, mean (SD) 8.1 (2.9) 10.7 (2.7) \0.001 8.2 (2.8) 10.8 (3.3) \0.001 6.5 (3.8) 10.7 (4.1) \0.001 8.6 (2.7) 11.1 (2.7) \0.001








0.28 57 (3:05) 8:48
(3:15)
0.82 8:58 (3:13) 8:45
(3:57)
0.59
Peak HR, mean (SD) 114 (18) 160 (18) \0.001 118 (19) 161 (17) \0.001 101 (14) 158 (19) \0.001 127 (21) 163 (16) \0.001
HR reserve, mean (SD) 89 (15) 84 (20) 0.15 87 (15) 84 (20) 0.25 83 (17) 84 (19) 0.78 83 (16) 85 (21) 0.64
% MPHR achieved, mean (SD) 70% (8%) 97% (8%) \0.001 73% (9%) 98% (7%) \0.001 67%
(9%)
96% (9%) \0.001 79%
(11%)
99% (7%) \0.001
Echo data available (%) 26 (70%) 160 (62%) 26 (53%) 162 (66%) 16 (73%) 171 (63%) 51 (65%) 137 (63%)
EF [55% 23 (89%) 141 (88%) 0.98 23 (89%) 143 (88%) 0.98 12 (75%) 144 (84%) 0.99 42 (82%) 115 (84%) 0.99
No limiting symptoms during
EST
6 (16%) 63 (24%) 0.99 7 (14%) 62 (25%) 0.99 4 (18%) 65 (24%) 0.99 9 (11%) 60 (28%) 0.94
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Association (NYHA) Class, systemic ventricular function and QRS
duration were noted. Occurence of appropriate therapies (defibrilla-
tion and/or anti-tachycardia pacing) was recorded using regular
device check data. Adverse events at the time of implantation and
during follow-up were also included.
Results: Out of 953 ACHD patients, ICDs were implanted in 22
(63.6% male, mean age 30.5 years; mean NYHA 1.8; mean QRS
duration 140). Transposition of the great vessels was the most com-
mon single diagnosis (36.4%). The majority of implants were for
primary prevention (86.4%). Over a median follow-up of 36 months,
six appropriate therapies occurred in five patients. All those with
appropriate therapies had reduced systemic ventricular function. Five
patients suffered adverse events (2 inappropriate shocks, 1 endocar-
ditis, 1 lead fracture, 1 lead repositioning).
Conclusions: ICD implantation in the ACHD population is infre-
quent but should be considered in selected patients including those
with complex congenital lesions. An appropriate therapy occured in
just over 20% of patients. As noted previously, systemic ventricle
dysfunction appears a major predictor of appropriate therapies.
Adverse event rate including number of inappropriate therapies was
low.
61. The Degree of QRS Shortening After
Resynchronization Therapy as a Predictor of LV
Reverse Remodeling: a Long Term Retrospective
Observational Study in a Single Irish Center
AlQaseer M, Jamshaid M, Collis R, Collins A, Sheahan R
Beaumont Hospital, Beaumont, Dublin
Background: It has been proven in several randomized multicenter
trials that a prolonged QRS duration is currently the only reliable
marker of electro-mechanical dyssynchrony. The aim of this study is
to assess the value of degree of QRS shortening after resynchroni-
zation therapy as a predictor of LV reverse remodeling in those
patients treated with CRT.
Methods: This is a retrospective observational study. The data was
obtained from a 10-year registry of CRT implants in a single center in
Ireland. We looked at all consecutive alive patients with CRT’s
implanted from 2001 until August 2010. We looked at their measured
QRS duration prior to implant and the QRS duration of their biven-
tricular paced complex. We then looked at the relationship of the
degree of QRS shortening to the change of ejection fraction (EF) at
least 6 months post implant using a bivariate analysis.
Study Results: 143 patients were identified with CRTs implanted
between 2001 and August 2010. They were divided into five cate-
gories based on the change of QRS duration from their native
complex to the biventricular paced complex. 8 patients had a reduc-
tion of their QRS duration by an increment of 0–5 ms, 23 had a
reduction of 6–15 ms, 27 showed improvement by 16–20 ms, and 78
showed reduction of QRS duration by more than 21 ms. Finally,
seven patients had biventricular paced complexes that were longer
than native complexes. Overall, there was a clear trend of improve-
ment in ejection fraction despite the degree of QRS shortening with
maximal benefit of improvement of ejection fraction in the reduction
of QRS duration by [21 ms where there was an improvement of EF
by 4.6% on average (from 29.3% to 33.9%). However, this did not
reach statistical significance (p = 0.08).
Conclusion: Although our results have not reached statistical sig-
nificance, a trend is certainly observed in our data to suggest that the
degree of QRS shortening may be used a predictor of LV reverse
remodeling in those patients treated with CRT.
62. Sprint Fidelis Lead Failure: a Report
from Northern Ireland
1Kodoth V, 2Gordon B, 1Ashfield K, 1Lau E, 1Wilson C, 2Chew EW,
1Roberts MJ
1The Heart Centre, Royal Victoria Hospital, Belfast, 2Cardiology
Department, Belfast City Hospital, Belfast
The Medtronic Sprint Fidelis family of leads are bipolar high-voltage
implantable cardioverter defibrillator (ICD) electrodes. The lead is
prone to malfunction, and in October 2007, were removed from the
market. The first Sprint Fidelis lead was implanted in Northern Ire-
land immediately after its release in December 2004. Longer survival
analysis for these leads can be made in view of early implant. Patient
follow up data was reviewed to determine the rate, characteristics and
mode of presentation of lead failure.
Methods and Results: A total of 260 patients had the Sprint Fidelis
leads implanted in Northern Ireland. All patients were followed up
**three monthly after lead alert was issued. In a combined follow up
of 1,004 years and a mean of 3.80 years, 26 of 260 (10%) leads
malfunctioned. Fourteen cases (53%) of lead malfunction were
detected after lead integrity alert software has been installed. Twenty-
three out of 198 (11.6%) of model 6931, 1 of 35 (2.8%) of model
6948 and 2 of 26 (7.6%) of model 6949 malfunctioned. The mode of
presentation was inappropriate shock in 13 (50%), alarm alert in 7
(27%) and high impedance and pace/sensing issues in 6 (23%). In
these patients, the previous three monthly lead checks were normal.
The median and mean duration for lead failure were 1,035 and
996 days. Two leads malfunctioned within 1 year, 2 within 2 years, 7
within 3 years, 11 within 4 years and 4 within 5 years of implant. The
Sprint Fidelis lead was removed and replaced in 17 (65%), 3 (11%)
patients had new pace/sense lead implanted, 4 (15%) had new ICD
lead implanted, 1 had device turned off and one patient is awaiting
intervention.
Conclusion: In our experience a high proportion of Sprint Fidelis lead
had to be replaced due to malfunction. Fifty percent of the lead failure
patients presented with inappropriate shocks. Three monthly lead
checks could not anticipate lead malfunction.
63. An Overview of Pacemaker and Device
Implantations in the West of Ireland
Canniffe C, Matiullah S, Aziz W, Boyle M, O’Sullivan C, Phelan D,
Daly K, Crowley J, Nash P, Sharif F, MacNeill B
Galway University Hospital, Galway
We carried out a retrospective review of pacemaker and cardiac
devices implantations in Galway University Hospital between 1
January 2010 and 31 December 2010.
Method: 309 patients were identified through the cardiac technician
database. A systematic review of implantation record, patient dis-
charge summaries and any recorded complications were noted.
Patient charts were reviewed if data from these records was insuffi-
cient for study purposes.
Results: 61.8% were male. The mean age was 75.3 years (range
15–98 years).We recorded patient characteristics relevant to the
potential development of complications of device implantation. 240
(77.6%) implants were first time procedures. 32 (13.2%) of these
were intracardiac defibrillators (ICD) or biventricular devices (Bi-
Vent), 67 (27.9%) dual chamber and 141 (58.7%) were single
chamber pacemakers. Subclavian access was the commonest mode
of implant, with brachiocephalic access in 10.7% of cases.
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Temporary pacing wires (TPW) were placed in 11% of patients
prior to their procedure. Repeat procedures (not including routine
box change for end of life) were reported in 10.6% of patients.
36.3% were secondary to complications that resulted in the need for
box +/- ead removal or new lead placement. A lead repositioning
procedure accounted for 27.2% of these. Upgrade of a device from
ICD to BiVent accounted for 21.2%. Infection was reported in 3.5%
of all cases. Pocket infections accounted for 45.5% of these. Of the
patients who developed infection 18.1% were diabetics, 36.3% had
an EF \49%. 72.7% of infections were related to repeat procedures
(p = 0.003), with box changes accounting for 50% of these. 45.4%
of these required removal of box +/- ead(s), with a further 9%
requiring removal of the box alone. Pocket problems were reported
in 4.2%. Haematomas accounted for 46% of these, followed by skin
erosion (38.4%) and pain (15.3%). 23% of these patients required an
evacuation, 38.4% required box removal. Of note, 38.4% of patients
who developed pocket complications had a history of anticoagula-
tion therapy. A further 15.3% were on dual antiplatelet therapy.
Lead failure was reported in 5.1%. 52.6% of these were patients
over 75 years old. The commonest reason was found to be lead
movement (53.8%). 81.2% of these patients required a repositioning
procedure.
Conclusion: We report the experience of a large volume centre for
pacemaker and cardiac device implantation. Based on our experi-
ence we would recommend exercising particular caution with
implantation procedures in elderly patients and paying close
attention to sterility and antibiotic regimes in those undergoing
repeat procedures.
64. Primary Percutaneous Coronary Intervention
‘‘False Positives’’
Dooley M, Belfast Trust pPCI Service Group
Belfast Trust, Belfast
Introduction: A primary percutaneous coronary intervention (pPCI)
service requires a simple method of activation to prevent unnecessary
delays to reperfusion. This can result in a significant proportion of
false positive referrals, which nationally runs between 10 and 20%.
This group of patients is often viewed as an unfortunate but necessary
distraction to the pPCI service.
Results: A 24/7 pPCI service was introduced in Belfast in
December 2009. In the 13 month period from February 2010 to
February 2011 a total of 236 patients activated the pPCI pathway
by having ST segment elevation on Electrocardiogram (ECG).
70.8% were male (mean age 61.5 years; range 30–99). Of the 236
patients, 24 (10%) were non-acute coronary syndrome (ACS) with
normal coronary arteries. Of these 24 patients, 5 had a past history
of Ischaemic Heart Disease but no evidence of current ACS with
normal cardiac troponin and 3 patients had isolated abnormal
ECGs (LBBB, early repolarisation, ST elevation over old infarction
with fast AF). However the remaining 16 patients had significant
cardiac pathology. The most common finding was myopericarditis,
present in ten patients. 3 patients had a Takotsubo’s cardiomyop-
athy and one patient a probable infiltrative cardiomyopathy.
Cardiovascular magnetic resonance (CMR) was used to clarify the
diagnosis in most patients. 2 further patients presented for the first
time with Brugada syndrome, one had easily inducible Ventricular
Fibrillation at electrophysiological study and received an Implant-
able Cardiac Defibrillator.
Conclusion: Far from being a distraction ‘‘false positive’’ patients
without ACS in a pPCI pathway often present with major cardiac
pathology.
65. Impact of Targeted Subspecialist Care Versus
Generalist Care on Lengths of Hospital Stay and Costs
across Common Diagnostic Groups
Groarke J, Maree AO, Owens P
Department of Cardiology, Waterford Regional Hospital, Waterford
Introduction: Many hospitals have a variety of medical subspecial-
ists involved in the care of acute medical admissions. This study aims
to compare lengths of hospital stay (LOS) for relevant subspecialist
care versus other subspecialist or generalist care across common
diagnostic categories in an Irish public teaching hospital.
Methods: All patients discharged over a 55 month period with the
following primary diagnoses were identified using the Hospital In-
Patient Enquiry (HIPE) system: exacerbation of chronic obstructive
pulmonary disease (COPD), pneumonia, acute myocardial infarction
(AMI), chest pain (CP), CHF, non-haemorrhagic stroke, and transient
ischaemic attack (TIA). To exclude outlying patients with extended
stays due to complex medical or social reasons, patients with LOS
exceeding 30 days were excluded from analyses. Differences between
LOS for subspecialist versus other subspecialist/generalist care for
each diagnostic group were investigated using the Student’s t test.
Cost savings were estimated.
Results: Comparative analyses of subspecialist versus other subspe-









n 494 1,345 \0.0001
Mean LOS (SD) 2.0 (2.0) days 3.6 (3.2) days
Pneumonia
n 80 712 \0.0001
Mean LOS (SD) 5.0 (4.7) days 8.8 (6.5) days
COPD exacerbation
n 200 1,637 0.0005
Mean LOS (SD) 6.8 (6.0) days 8.4 (6.0) days
AMI
n 335 679 0.43
Mean LOS (SD) 7.0 (5.0) days 7.5 (6.0) days
CHF
n 166 770 0.15
Mean LOS (SD) 8.6 (6.5) days 9.5 (6.5) days
Stroke
n 226 282 \0.0001
Mean LOS (SD) 10.9 (7.8) days 8.3 (6.1) days
TIA
n 78 388 0.21
Mean LOS (SD) 4.4 (4.4) days 5.1 (4.4) days
If patients with primary diagnoses of CP, COPD exacerbations and
pneumonia were triaged to relevant subspecialist care, 1,632 bed days
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and Euro1,082,824 would be the potential annual savings for this
hospital.
Conclusions: Subspecialist care of patients with CP, COPD exacer-
bations and pneumonias achieves significant reductions in LOS in
comparison to care delivered by other medical subspecialists. Cost
savings of targeting relevant subspecialist care to these diagnostic
groups could be significant at an institutional and national level.
Specialty-specific care reduced LOS in selected diagnostic groups
only. Studies to clarify which diagnostic groups benefit most from
targeted subspecialist care are necessary.
66. Constrictive Pericarditis, Still a Diagnostic
Challenge in the Twenty-First Century: an Irish Single-
Centre Retrospective Cohort Study
Moran DP, Khalil A, O Donnell A, Kiernan TJ
Department of Cardiology and Cardiothoracic Surgery, University
College Cork, Cork University Hospital, Cork
Constrictive pericarditis is a condition of a thickened pericardium,
resulting in a loss of elasticity leading to haemodynamic compromise.
Often this is a late sequela to an inflammatory condition of the
pericardium. Classically the risk factors for constrictive pericarditis
are tuberculous infection, radiation therapy and cardiotomy. Despite
extensive testing with 2-dimensional and Doppler echocardiography,
cardiac CT, CMR and conventional cardiac catheterization, the
diagnosis may remain equivocal.
Purpose: This is the first review of this cohort within the south of
Ireland. We reviewed the diagnostic modalities used, reviewed the
haemodynamics obtained and identify likely aetiology in each case.
Methods: Patients were identified retrospectively from 2003 to 2007
using surgical database analysis. Medical charts, angiographic, com-
puted tomography, echocardiographic data, MRI and histology
reports were obtained.
Results: 10 patients were identified from post-pericardiectomy
records. Median age was 56.6 (±23.6) years. 7 male (70%), 3 female.
Previous TB infection was identified in 2 patients (20%). Post-car-
diotomy (MVR) as an aetiology was identified in 1 patient.
Mediastinal radiotherapy (NHL) was the causative agent in 1 patient.
Therefore, 60% of cases were deemed Idiopathic Constrictive Peri-
carditis in terms of aetiology. Echocardiographic data suggested
constrictive pericarditis in five patients (50%) with the presence of
abnormal ventricular septal motion and restrictive mitral inflow
velocities with respiratory variation. CT reporting suggested con-
strictive pericarditis in five patients (50%), commenting on pericardial
thickening/calcification.
MRI was used to further elucidate diagnosis in four patients (40%).
Classic invasive haemodynamic tracings of constrictive pericarditis
(‘‘dip and plateau’’ of LV pressure +/- qualisation of end-diastolic
pressures in all 4 chambers) were identified in all patients.
Conclusions: The aetiology of constrictive pericarditis in the twenty-
first century continues to be dominated by Idiopathic Constrictive
Pericarditis. Invasive haemodynamics remains the chief diagnostic
tool in identifying cardiac constriction, and imaging modalities con-
tinue to lag behind.
67. Percutaneous Left Atrial Apendage Closure
(PLAATO): 5-year Outcomes
Neylon MA, O’Connor SA, Mylotte D, McAdam B, Sheahan R,
Foley D
Beaumont Hospital, Beaumont, Dublin
Stroke is the third leading cause of mortality and a leading cause of
morbidity worldwide. Cardioembolic strokes are associated with the
worst long term prognosis and most commonly occur in patients with
Atrial Fibrillation. Despite the proven efficacy of oral anticoagulation
it remains underutilized, difficult to manage and associated with
significant morbidity and bleeding complications. Newer agents such
as Dabigatran address some of these issues, however there remains a
cohort of patients with absolute contraindications to oral anticoagu-
lation in whom occlusion of the Left Atrial Appendage (LAA) has
had favourable short and medium term outcomes. We present our
5 year follow-up with the PLAATO system. We performed a pro-
spective, single-centre observational study in which LAA occlusion
was attempted in between July 2005 and October 2006. All patients
had contraindications to warfarin. The primary end-point was the
incidence of stroke. Clinical follow-up at a mean of 65 months (range
54–68) was carried out by review of case notes and telephonic
interview. 16 patients had successful device placement. Mean patient
age was 73.2 years. 3 patients died during follow-up of non cardiac
related complications. Another patient had the device removed
11 month post placement when undergoing mitral valve surgery for
progressive MR. 5-year data is available on 12 patients. Their average
CHADS2-vasc score for the remaining cohort was 5 estimating an
adjusted stroke rate of 6.7% per year. There was one stroke during
follow-up. This occurred 28 months after implant when on asprin
only. Following this dual antiplatelet therapy was recommenced and
no further events have occurred. No other systemic embolic events or
complications related to the PLAATO were seen. In conclusion, in
this small series LAA occlusion with the PLAATO device in the
longer term decreases the risk of stroke in a high risk cohort of
patients with atrial fibrillation deemed unsuitable for oral
anticoagulation.
68. Real World Costs of Non-Cardiac Chest Pain
Admissions
Groarke J, O’Brien J, Go G, Susanto M, Owens P, Maree AO
Department of Cardiology, Waterford Regional Hospital, Waterford
Introduction: 65% of patients presenting with chest pain (CP) to
emergency departments are admitted. The majority will have a non-
cardiac aetiology for their symptoms. The aim of this study was to
describe the cost of non-cardiac CP admissions to a tertiary hospital
and identify areas of greatest expenditure.
Methods: 80 consecutive patients admitted with CP between 15/1/11
and 12/3/11 were prospectively followed. Demographics, investiga-
tions, TIMI risk score, lengths of stay (LOS) and discharge diagnoses
were recorded for all patients. Admissions of patients with a discharge
diagnosis of non-cardiac CP were micro-costed.
Results: Of 80 patients with a mean age (SD; range) = 61 (14;
35–94) years [mean LOS = 5.5 (3.8; 1–16) days; mean TIMI risk
score = 2.2 (1.6; 0–6)], a diagnosis of acute coronary syndrome was
established in 22 (28%) [mean age = 67 (14; 43–94) years; 14 (64%)
male; mean TIMI risk score = 3.1 (1.2; 0–5); mean LOS = 7.7 (4.3;
2–16)]. The 34 patients with a discharge diagnosis of non-cardiac CP
[mean age = 54 (11; 35–74); 20 (59%) male; mean TIMI risk
score = 1.4 (1.5; 0–5)] had a mean LOS of 3.8 (2.6; 1–11) days. Only
2 (6%) were weekend discharges. The mean intervals in days from
admission to EST (n = 20), coronary angiography (n = 3) and CT
pulmonary angiography (n = 5) were 2.7 (1.5; 1–7) days, 6.7 (0.6;
6–7) and 1.6 (1.3; 1–4), respectively. The total cost for all 34 admis-
sions was Euro129,251 with the breakdown of costs as follows: bed
day/radiology/cardiac/laboratory investigation costs = Euro118,170
(91%)/Euro4,900 (4%)/Euro3,662 (3%)/Euro2,519 (2%). The mean
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cost per non-cardiac CP admission was Euro3,802 (Euro2,381;
Euro1,110–10,708).
Conclusion: The mean cost of admission and LOS for a patient with a
discharge diagnosis of non-cardiac CP of Euro3,802 and 3.8 days are
higher than the respective figures quoted by National Casemix Pro-
gramme of Euro1,596 and 2.8 days. Bed day costs are the greatest
component of overall costs. Delays from admissions to diagnostic
tests are significant and percentage of weekend discharges is very
low. Strategies to reduce delays to testing and increase weekend
discharges would likely reduce LOS with cost savings.
69. Evolving Trends of Intra-Aortic Balloon Pump
Counterpulsation (IABP) Usage in a Tertiary Cardiac
Transplant Centre from 2008 to 2010
Anwar AA, Roy A, Mustafa G, Joyce E, Buckley U, Nashat H,
Sugrue D, McCann H, Blake G, Mahon N
Mater Misericordiae Hospital, Dublin
Background: The growing prevalence and complexity of end-stage
heart failure, coupled with declining cardiac transplant rates, have
created an increasing demand for prolonged inotropic and intra-aortic
balloon pump (IABP) support in patients awaiting more definitive
destination therapy.
Aim: The aim of this study was to document patterns and outcomes of
IABP usage in an era of more efficient management of acute coronary
syndromes and an increasing burden of advanced heart failure.
Methods: All patients who received an IABP between 2008 and 2010
were identified via cardiac catheterisation lab records. Charts and
computer records were examined retrospectively.
Results: 118 patients had IABP insertion in this period. Median age
was 65.5 ± 13.7 years. Male 81 (68.6%).
In our cohort, IABP remained in vivo for a total of 2,121 days.
Decompensated CCF had the longest duration of IABP use,
1,824 days.
IABP related adverse events occurred in 47 patients.
Adverse event Decompensated
CCF (n = 32, %)
All other patients
(n = 86, %)
IABP-related deaths 0 (0%) 3 (3%)
Major embolic event 1 (3%) 1 (1%)
HITS 2 (6%) 1 (1%)
Retroperitoneal bleed 2 (6%) 0 (0%)
Major bleeding 4 (13%) 4 (5%)
Culture +ve IABP 6 (19%) 3 (3%)
Culture +ve PUO 2 (6%) 2 (2%)
Culture -ve PUO 7 (22%) 9 (10%)
In-hospital mortality was 36 (30.5%). Cardiac death occurred in
28 (23.7%). Nosocomial septicaemia caused 5 (4.2%) deaths. IABP-
related death in 3 (2.5%) were due to ischaemic bowel, Lepirudin
associated intracranial haemorrhage, and renal ischaemia.
Conclusion: End stage heart failure accounts for a significant pro-
portion of indications for IABP, and is associated with prolonged
therapy and a consequent higher complication rate. This highlights the
need both for optimization of organ donation, and continued devel-
opment of alternative long-term haemodynamic support options,
including ventricular assist devices as bridges to transplantation or
destination therapy.
70. Atrial Fibrillation in Paced Rhythm: ‘‘Under-
Diagnosed and Under-Recognized’’
Alkhalil M, Quinn S, Magill P, Tauro R, Prabhavalkar S
Belfast Health and Social Care Trust, Belfast
Introduction: Atrial fibrillation (AF) is the most common cardiac
arrhythmia, occurring in 1–2% of the general population [1]. AF
confers a fivefold risk of stroke and effective treatment strategies exist
which have shown to reduce thromboembolic events. There is only
scant published evidence demonstrating the importance of diagnosing
AF in patients with paced rhythm as this can be a potential pitfall
leading to a diagnostic error [2].
Aim: We aimed to gauge the diagnostic ability of doctors to recognize
AF in paced rhythm based on Electrocardiograph (ECG) interpretation.
Method: We formed a questionnaire involving four questions based
on an ECG showing paced rhythm and AF. A brief clinical history
was provided and the participants were asked to identify the rate, axis,
rhythm and whether they would consider any further intervention.
Fifty-two participants were involved from 3 hospitals within the
Belfast trust. These included Foundation and Core trainees, Specialty
trainees and Consultants in Medicine. The responses were obtained
anonymously.
Results: 19% (10 out of 52) doctors identified AF rhythm correctly
and only half of them (9.6%) recommended warfarin. 63% (33 out of
52) doctors reported paced rhythm with no further comment on the
missing P waves. Interestingly, more than 60% of doctors (32 out of
52) identified the axis incorrectly.
Conclusions: Our study demonstrates under-recognition of this fairly
common condition among hospital doctors. It highlights the need for
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increasing awareness among trainees in recognising this pitfall and
diagnosing AF in patients with paced rhythm in order to reduce
mortality and morbidity associated with this condition.
References
1. European Society of Cardiology Clinical practice guidelines
(2010).
2. Treatment of underlying atrial fibrillation: paced rhythm obscures
recognition. J Am Coll Cardiol. 2000;36(3):784–787
71. Cardiac Contribution to the Workload of Medical
Assessment Units (MAUs)
Groarke J, McMenamin L, McConway L
Medical Assessment Unit, Waterford Regional Hospital, Waterford
Introduction: The role of MAUs in management of medical patients
and their staffing is very topical. The aim of this study is to describe
the type of patient presenting to, and resource utilisation by, a MAU
of a tertiary referral hospital.
Methods: A prospective, observational cohort study was performed.
Consecutive patients presenting to a MAU between 31/1/11 and 3/4/
11 were invited to participate. Demographics, presenting complaint,
investigations, and management plan were recorded for each patient.
30-day outcomes were sought for all patients.
Results: Of 74 patients [mean age (SD; range) = 47 (17; 16–87) years;
46 (62%) female], cardiovascular symptoms were the presenting
complaint of 38 (51%): chest pain (CP) alone in 16 (22%), CP with
dyspnoea in 9 (12%), palpitations in 6 (8%), presyncope/syncope in 4
(6%) and dyspnoea in 3 (4%). 34% of primary diagnoses were cardiac in
nature: 15 (20%) cardiac CP, 4 (5%) symptomatic ectopics, 3 (4%)
hypertension, 2 (3%) atrial fibrillation, 1 (1.5%) cardiac syncope.
Echocardiograms, exercise stress tests, 24 h holter and blood pressure
monitors were performed on 37 (50%), 20 (27%), 19 (25%) and 12
(15%) of patients, respectively. The majority of cardiac investigations
were performed on day of initial presentation. Priority access to cardiac
investigations was identified as a primary factor in avoiding admission
in 41 (64%) of the 64 patients not admitted. The mean spend on
investigations in the MAU for patients with CP who were not admitted
was Euro266 (versus inpatient Casemix mean cost per patient admitted
with non-cardiac CP of Euro1,596). Admission was avoided in 87% of
patients presenting with CP. Overall 30 day mortality and unplanned
readmission rates were 0% and 3% (n = 2), respectively. Patient sat-
isfaction with MAU assessment was high (n = 73; 99%).
Conclusions: Cardiovascular symptoms are the presenting complaint
of half of patients assessed in a MAU. Uptake of cardiac investiga-
tions is high and priority access to cardiac investigations reduces
admissions. MAUs can achieve cost efficient assessment of patients




72. Cost and Resource Implications of Defibrillator
Lead Fractures
1,2Groarke J, 2Buckley U, 1Collison D, 2O’Neill, 2Mahon N, 1Foley B
1St. James’s Hospital, Dublin; 2Mater Misericordiae University
Hospital, Dublin
Introduction: Implantable cardioverter defibrillator (ICD) lead fail-
ure occurs at annual rates ranging from 0.18 to 3.6%. With growing
numbers of ICD recipients, management of lead-related complica-
tions is set to be an ongoing clinical challenge. The aim of this study
is to describe the cost of managing patients with lead fractures.
Methods: Lead fractures were identified by chart review of all
patients who had undergone lead extraction and/or replacement
between 01/01/06 and 28/02/2011 in two tertiary referral hospitals.
Details of lead fracture and replacement were recorded for each
patient. Follow up data were sought. Data were used to microcost
admissions.
Results: 24 patients [mean age (SD; range) = 54 (16; 16–80) years;
male:female = 7:1] were identified with lead failure at a mean interval
from time of implant of 2.9 years (1.9 years; 20 days–9 years). Lead
fractures were identified as a result of inappropriate shock delivery in
16 (67%), routine device check in 5 (20%) and early detection soft-
ware in 3 (13%). The mean number of inappropriate shocks delivered
was 10 (3; 1–60). 23 (96%) patients underwent lead replacements. The
mean length of stay in a monitored bed was 5.9 (8.6; 1–43) days. The
fractured lead was successfully extracted by simple traction in 9 (38%)
patients. 6 of 23 (26%) of patients received a new generator. Com-
plications were recorded for 3 patients (12.5%). 2 (8%) patients were
readmitted to hospital within 30 days with a device related compli-
cation. 30-day and 1-year mortality were 0% and 4%, respectively.
Costs of bed days (Euro150,894), new generators (Euro82,500),
catheterisation laboratory staffing (Euro13,499), ambulance transfers
(Euro9,100), laboratory investigations (Euro1,723), other radiological
and cardiac investigations (Euro1,981) yield an average cost of man-
aging each patient with lead fracture of Euro10,800.
Conclusions: Management of defibrillator lead fractures is associated
with significant cost and bed day consumption. With expanding
indications for ICD implantation and a growing population of younger
ICD recipients, the prevalence of lead fractures is likely to increase
with cost and resource implications.
73. Riata Lead Failure: a Report from Northern Ireland
(NI) Riata Lead Screening Programme
Kodoth V, Cromie N, McEneaney D, Wilson C, Lau E, Roberts MJ
Royal Victoria Hospital, Belfast
The St. Jude Medical Riata family of leads are high voltage
implantable cardioverter defibrillator (ICD) leads. Insulation related
inappropriate shocks were noted in a patient in November 2006 and
sporadically since then. The objectives of the NI Riata lead screening
programme were to identify insulation defects, risk factors, define
prevalence, determine management plan and develop a follow up
programme.
Method and Results: All patients with Riata lead in NI were
screened with high resolution fluoroscopy and lead parameters
checked. Out of 212 patients with Riata lead, 164 were males and 48
females. Mean age at the time of implantation was 62.7 ±
13.40 years. Lead model 1580 was implanted in 16 patients, 1582 in
69, 1570 in 8, 1572 in 5, 7000 in 60, 7002 in 41, 1571 in 2, 1742 in 2,
7040 in 6 and 7022 in 3 patients. One hundred and sixty-five out of
212 were screened as 28 were dead, 5 had the lead explanted prior
screening, 3 excluded and 11 did not attend the screening programme.
Mean screening period after implantation was 3.98 ± 1.43 years.
After screening 25 (15%) were classified as positive, 3 (1.8%) bor-
derline and 137 (83%) negative for insulation breach. Five (3%) out
of the 25 presented with spontaneous lead issues and 20 (12%) were
identified by fluoroscopy. Seven patients had the defective lead
removed. The rest of the patients are closely monitored with
3 monthly fluoroscopy and ICD parameter check.
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Conclusion: A significant proportion (15%) of patients had a insu-
lation breach on screening. Twenty percent of the patients with
insulation defect presented with clinically significant events. Insula-
tion breach cannot be detected with Chest X-ray or by checking ICD
parameters and requires high resolution fluoroscopic imaging. Further
surveillance plans for negative and borderline category need to be
developed and agreed internationally.
74. Atrial Fibrillation in Ireland. Highly Symptomatic
and Associated with a High Incidence of Co-
Morbidities: Insights from the RealiseAF Registry
O’Neill J, Keelan T, Galvin J, Conway M, Gumbrielle T, Sheahan R,
McFadden E, Murphy R, McCaffrey D
On behalf of the RealiseAF Irish Investigators
Aims: Atrial Fibrillation (AF) is the most commonly encountered
arrhythmia in contemporary clinical practice with heterogeneity in
presentation, associated co-morbidities and symptoms. We sought to
describe a cohort of Irish patients with AF, who participated in the
RealiseAF registry.
Methods: RealiseAF is an international cross-sectional registry of
patients with any history of AF in the previous 12 months performed
in 26 countries on 4 continents from randomly selected samples of
cardiologists and internists. Data were gathered between October
2009 and May 2010 in eight Irish centres.
Results: Of 229 patients enrolled in 8 Irish centres (67% male), mean
age 68 + 12 years, 25% were in sinus rhythm, and 36% had con-
trolled AF (heart rate\80 bpm at rest). The vast majority (87%) had
at least one symptom referable to AF, with dyspnoea (40%), fatigue
(37%) and chest pain (14%) the most common features. Most (90%)
had structural heart disease and 10% had ‘‘lone AF’’. Alcohol (9%)
and inter-current infection (8%) were the most commonly described
precipitants. Co-morbidities were frequent with coronary artery dis-
ease (32%), valvular heart disease (19%) and stroke (9%) being
among the most common. In keeping with the relatively high stroke
incidence, 43% had a CHADS2 score [2. Almost 1/3 (32%) of
patients enrolled had been hospitalised for cardiovascular morbidities
in the preceding year.
Conclusions: AF remains a huge therapeutic challenge in Ireland, as
in other developed market economies. Despite its prevalence, and its
perceived benign course, many patients remain symptomatic with
limiting symptoms.
75. Long Term Outcomes in Patients Receiving Cardiac
Resynchronization Therapy: a 10-year Single Center
Irish Registry
AlQaseer M, Jamshaid M, Collis R, Collins R, Wotchcorn R, Sheahan
RG
Beaumont Hospital, Dublin
Background: To our knowledge, there are no registries in the
Republic of Ireland that have followed up patients implanted with
CRT, assessing improvement of symptoms, mechanical and electrical
dyssynchrony, and mortality benefit. The aim of this registry is to
characterize our patient population that are treated with CRT with
view to quantifying the long-term effect of CRT on clinical status,
improvement of echocardiographic parameters, and survival benefit.
Methods: This is a retrospective observational study that looked at
consecutive patients that have been implanted with CRT in a single
center in Dublin over the past 10 years. We registered their baseline
demographics and assessed their indication for implantation. We then
looked at their most current office visit to establish their most recent
NYHA status, QRS duration, and their most recent EF. All mortalities
were noted along with documentation of the cause of death and
interval between time of death and the date of CRT implant.
Study Results: 202 CRTs were implanted between 2001 and 2011 in
our center. Average age of our patient population was 71 years of age.
87% of the patients were male. 21 of the implanted devices were
CRT-Ps and the rest were CRT-Ds. 69% of the patients had an
underlying ischemic cardiomyopathy. Mean follow up was 5 years.
With view to indications of CRT implantation: average Ejection
Fraction at time of implant was 28.8% with a LV end systolic
dimensions of 6.1 cm, the average QRS duration was 164.8 ms, the
average NYHA classification at time of implant was 3.1. The ejection
fraction rose to 34.6% on average after CRT therapy and the QRS
duration was shortened to 131.2 ms. In terms of functional classifi-
cation, the patients’ NYHA status improved by an average of 1.2
classes. 71% of the patients were on Aspirin, 82% on beta-blocker
therapy, 74% on ACE-inhibitor/ARB therapy, and 84% were on
diuretics prior to implantation. This was similar to their treatment
regimen post implantation. However, a trend was noted that the
required diuretic dosages were reduced after implantation due to
improvement in symptoms. Out of the 202 patients, 45 died (22%). 8
of those had their had devices implanted with 1 year of their
mortality.
Conclusion: This is observational retrospective analysis of our cen-
ter’s experience in CRT implantation over the past 10 years. It shows
trends in improvement in EF, NYHA status, and electrical dyssyn-
chrony with this therapy in our patient population with mortality
benefit and long term outcomes that are comparable to the interna-
tional data.
76. Use of the Stand-Up Test for the Long QT
Syndrome in a Screening Population for Inherited
Cardiac Diseases
McGorrian C, Constant O, O’Donnell C, Keelan T, Galvin J, O’Neill
J, Mahon N
The Heart House, Mater Misericordiae University Hospital, Dublin
Objectives: Detection of the long QT syndrome (LQTS) in screening
populations can be clinically challenging, as QT prolongation can
vary. The stand-up test for LQTS examines QT interval response to
the tachycardia provoked by standing. We describe initial experience
with this test in a high risk screening population.
Methods: Prospective, observational study. Patients who were rela-
tives of SADS victims, or who had a possible personal or family
history of LQTS, were offered stand-up testing if they had changes
suspicious for LQTS on initial screening. Patients lay recumbent for
10 min, then stood up for 5 min, with continuous 12-lead ECG
printout. The QT interval and preceding RR were measured at max-
imal bradycardia, maximal tachycardia, and maximal QT stretching
(T wave approaching the next P wave). Using the suggested QT cut-
offs (**Viskin et al. 2010), ECG, Holter measurements, and Schwartz
score were compared by stand-up test findings.
Results: Stand up tests were available on 30/35 patients. Only seven
patients (23.3%) had QTc C450 ms (in males) or C470 (in females)
on their screening ECG. In total, 17 persons (56.7%) had a QTc at
maximal tachycardia or stretch which reached Viskin criteria
(‘‘positive stand up’’), 10 of whom had normal range baseline ECG
QTc. Persons with a positive stand-up test had longer screening ECG
QTc (mean 440.81, SD 38.82 vs. 411.54, SD 26.53, p = 0.03), and
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longer mean QT on Holter (mean 461.18, SD 27.30 vs. 435.36, SD
18.92, p = 0.02). A positive stand-up test was associated with a
100.0% (95% CI 39.7, 100.0%) sensitivity and 50.0% (95% CI 29.9,
70.1%) specificity for a Schwartz score of C3 (AUROC 0.75).
Conclusions: The stand-up test identifies persons with higher LQTS
risk and may prove useful in persons with non-diagnostic ECG
findings. Further genetic mutation analysis will enhance understand-
ing of the diagnostic capabilities of this test.
77. Out of Hospital Cardiac Arrest: a Review
of Ambulance Data in Dublin Mid-Leinster
1Burke J, 2Kelleher C
1UCD School of Nursing Midwifery and Health Systems, Dublin
2UCD School of Public Health, Physiotherapy and Population
Science, Dublin
Introduction: Ireland, at last, has an out of hospital cardiac arrest
(OHCA) register. Previously there was no system of recording in
cardiac arrest management in Ireland and very few published studies.
Objective: To review existing ambulance data to generate informa-
tion on the demographics of those who suffer these emergencies,
circumstances of their collapse, emergency medical system response
and on outcomes.
Design: A retrospective review of 32, 124 ambulance patient-care
report forms (PRFS) filed for the year 2008. Data were extracted on
those who had suffered a collapse or cardiac and/or respiratory
emergency. Variables for the subgroup of cardiac arrests cases
(n = 250) were recorded according to Utstein criteria and in con-
cordance with the then budding OHCA register. For data protection
reasons, this study’s outcome was status at transfer to hospital care.
Setting: The operational area for the Region’s ambulance division, an
area of 46,380 km2, population 1,499,705 (Central Statistics Office
2006).
Results: Overall, 11% of the 32,124 PRFs were classified as collapse,
9% as chest pain and/or other cardiac. Approximately 1% (n = 250)
were classified as cardiac arrest. Of the 214 non traumatic cardiac-
arrest cases, 64% were male, mean age 66 years. Fourteen percent
had spontaneous circulation on arrival at hospital. Almost two-thirds,
(64.5%) occurred in the home while\18% occurred in a public place.
Initial analysis with Chi-square test for independence indicates a
significant association between outcome and cardiac arrest rhythm,
urban/rural location and whether the arrest was witnessed or not.
Conclusion: It would appear that responding to cardiorespiratory
emergencies accounted for 10.5% of the Region’s EMS workload.
This study provides valuable information for pre-hospital care plan-
ning particularly in light of recent directives from the Irish Health
Information and Quality Authority in relation to response time indi-
cators for pre-hospital emergency care.
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